  Office of Clinical Research  
   
 
 
Confidential and Proprietary Information of the Trustees of the University of Pennsylvania  
8032  Maloney Bldg. | [ADDRESS_743817] | Philadelphia, PA  [ZIP_CODE] -6061 | Tel: (215) 662- 4484 | Fax: 215- 614-0378  
www.med.upenn.edu/ocr  
 
 
 
PROTOCOL #842996 (PENNCCP- 01) AN OPEN- LABEL, SINGLE ARM, 
PHASE 1, SAFETY AND EXPLORATORY  EFFICACY STUDY OF 
CONVALESCENT PLASMA FOR SEVERELY ILL  MECHANICALLY 
VENTILATED PARTICIPANTS WITH COVID- 19 CAUSED BY [CONTACT_7544]-
COV -2 
 
[STUDY_ID_REMOVED]  
 
 
VERSION DATE : 28-AUG- [ADDRESS_743818](S) : Penn COVID-19 Convalescent Plasma 
STUDY NUMBER(S):  IRB Number  842996 
Other Protocol Identifiers   PennCCP -01 
PROTOCOL(S) TITLE:  An Open -Label, Single arm, Phase 1, Safety and Exploratory 
Efficacy Study of Convalescent Plasma for Severely Ill Mechanically Ventilated  Participants with COVID -19 Caused by 
[CONTACT_7544] -CoV-2 
IND NUMBE R [ZIP_CODE] 
REGULATORY SPONSOR:  University of Pennsylvania 
[ADDRESS_743819]; 
8032 Maloney Building Philadelphia, PA, [ZIP_CODE] 
FUNDING SPONSOR(S):  University of Pennsylvania 
MEDICAL DIRECTOR Kath arine J. Bar, MD 
ORIGINAL PROTOCOL DATE:  15-April -2020 
VERSION NUMBER:  Version 4 
VERSION DATE:  28-Aug-2020 
    
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 2 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
Table of Contents  
Clinical Research Protocol  .................................................................................................................. 1  
1 Study Summary  ............................................................................................................................ 7  
1.1 Synopsis  .................................................................................................................................... 7  
1.2 Key Roles and Study Governance ........................................................................................ 13  
1.3 Schema  .................................................................................................................................... 13  
2 Introduction and Rationale  ....................................................................................................... 14  
2.1 Study Rationale ...................................................................................................................... 14  
2.2 Background ............................................................................................................................ 14  
2.2.1  COVID-19 ......................................................................................................................... 14  
2.2.2  Passive Immunotherapy in Coronavirus Disease ......................................................... 14  
2.2.3  Passive Immunotherapy in Other Viral Infection  ........................................................ 15  
2.3 Risk/Benefit Assessment  ........................................................................................................ 16  
2.3.1  Known Potential Risks  .................................................................................................... 16  
[IP_ADDRESS]  Risk of Plasma Transfusions..................................................................................... 16  
[IP_ADDRESS]  Risk of Antibody -Mediated Enhancement (ADE) of Infection  ............................. 17  
[IP_ADDRESS]  Risk of Antibody -Mediated Acute Lung Injury  ..................................................... 17  
[IP_ADDRESS]  Risk of Decreased Protective Immunity  .................................................................. 18  
[IP_ADDRESS]  Risk of Plasma Transfusions Interaction with Immunization ............................... 18  
[IP_ADDRESS]  Risk of Phlebotomy .................................................................................................... 18  
[IP_ADDRESS]  Risk of Nasopharyngeal Swab .................................................................................. 19  
[IP_ADDRESS]  Risk of Oropharyngeal Swab .................................................................................... 19  
[IP_ADDRESS]  Risk of Endotracheal Aspi[INVESTIGATOR_337] ................................................................................. 19  
2.3.2  Known Potential Benefits  ................................................................................................ 19  
[IP_ADDRESS]  Benefits of Treatment  ................................................................................................ 19  
[IP_ADDRESS]  Alternatives  ................................................................................................................ 19  
2.3.3  Assessment of Potential Risks and Benefits  ................................................................... 19  
[IP_ADDRESS]  Assessment of Potential Risks and Benefits in Pregnant Individuals  ................... 20  
3 Study Objectives and Endpoints  ............................................................................................... 21  
3.1 Primary Objectives  ................................................................................................................ 21  
3.2 Secondary Objectives and Endpoints  .................................................................................. 21  
3.3 Exploratory Objectives and Endpoints ............................................................................... 23  
4 Study Plan  ................................................................................................................................... 25  
4.1 Study Design  ........................................................................................................................... 25  
4.2 Scientific Rationale for Study Design  .................................................................................. 25  
4.3 Justification for Dose ............................................................................................................. 26  
4.4 End of Study Definition  ......................................................................................................... 26  
5 Study Population ........................................................................................................................ 27  
5.1 Inclusion Criteria  ................................................................................................................... 27  
5.2 Exclusion Criteria  .................................................................................................................. 27  
5.3 Lifestyle Considerations  ........................................................................................................ 27  
5.4 Screen Failures  ....................................................................................................................... 27  
5.5 Strategies for Recruitment and Retention  ........................................................................... 28  
5.5.1  Recruitment  ...................................................................................................................... 28  
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 3 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
5.5.2  Retention  ........................................................................................................................... 28  
5.5.3  Costs  .................................................................................................................................. 28  
6 Study Intervention ...................................................................................................................... 29  
6.1 Study Intervention(s) Administration  .................................................................................. 29  
6.1.1  Study Intervention Description ...................................................................................... 29  
6.1.2  Dosing and Administration ............................................................................................. 29  
6.2 Preparation/Handling/Storage/Accountability ................................................................... 29  
6.2.1  Acquisition and Accountability  ...................................................................................... 29  
6.2.2  Formulation, Appearance, Packaging, and Labeling ................................................... 30  
6.2.3  Preparation  ....................................................................................................................... 30  
6.3 Measures to Minimize Bias: Randomization and Blinding  ............................................... 30  
6.4 Study Intervention Compliance ............................................................................................ 30  
6.5 Concomitant Therapy ........................................................................................................... 30  
6.5.1  Rescue Medicine ............................................................................................................... 30  
7 Study Intervention Discontinuation and Participant Discontinuation/Withdrawal  ............ 31  
7.1 Discontinuation of Study Intervention ................................................................................. 31  
7.2 Participant Discontinuation/Withdrawal from the Study  ................................................. [ADDRESS_743820] To Follow- Up ................................................................................................................. 31  
8 Study Assessment and Procedures  ............................................................................................ 32  
8.1 Efficacy Assessments  ............................................................................................................. 32  
8.1.1  Screening Procedures  ...................................................................................................... 32  
[IP_ADDRESS]  Screening Procedures in Pregnant Women  ............................................................. 33  
8.1.2  Measures of clinical support, limitations and infection control  .................................. 33  
8.1.3  Ordinal Scale  .................................................................................................................... 34  
8.1.4  National Early Warning Score (NEWS) ........................................................................ [ADDRESS_743821] Values 
or Abnormal Clinical Findings  ....................................................................................... 36  
8.4 Adverse Events and Serious Adverse Events  ...................................................................... 37  
8.4.1  Definition of Adverse Events (AE)  ................................................................................. 37  
8.4.2  Definition of Serious Adverse Events (SAE)  ................................................................. 37  
8.4.3  Classification of an Adverse Event ................................................................................. 38  
[IP_ADDRESS]  Severity of Event  ........................................................................................................ 38  
[IP_ADDRESS]  Relationship to Study Intervention .......................................................................... 38  
[IP_ADDRESS]  Expectedness  .............................................................................................................. 39  
8.4.4  Time Period and Frequency for Event Assessment and Follow -Up ........................... 39  
8.4.5  Adverse Event Reporting  ................................................................................................ 40  
[IP_ADDRESS]  Reporting Period  ........................................................................................................ 40  
[IP_ADDRESS]  Investigator Reporting: Notifying the Study Sponsor ............................................ 40  
[IP_ADDRESS]  Investigator Reporting: Local Reporting Requirements  ....................................... [ADDRESS_743822]  ................................................................................................ 42  
8.4.9  Reporting of Pregnancy .................................................................................................. 42  
8.5 Unanticipated Problems  ........................................................................................................ 42  
8.5.1  Definition of Unanticipated Problems (UP)  .................................................................. 42  
8.5.2  Unanticipated Problem Reporting  ................................................................................. 42  
8.5.3  Reporting Unanticipated Problems to Participants  ..................................................... 43  
9 Statistical Considerations .......................................................................................................... 44  
9.1 Statistical Hypotheses  ............................................................................................................ 44  
9.2 Sample Size Determination  ................................................................................................... 45  
9.3 Populations for Analyses ....................................................................................................... 46  
9.4 Statistical Analyses ................................................................................................................ 46  
9.4.1  General Approach  ........................................................................................................... 46  
9.4.2  Analysis of the Primary Endpoint(s) .............................................................................. 46  
9.4.3  Analysis of the Secondary Endpoint(s)  .......................................................................... 47  
9.4.4  Safety Analyses ................................................................................................................. 47  
9.4.5  Baseline Descriptive Statistics  ........................................................................................ 48  
9.4.6  Planned Interim Analyses  ............................................................................................... 48  
9.4.7  Sub-Group Analyses ........................................................................................................ 48  
9.4.8  Tabulation of Individual Participant Data  .................................................................... 49  
9.4.9  Exploratory Analyses ...................................................................................................... 49  
10 Supporting Documentation and Operational Considerations  ................................................ 50  
10.1  Regulatory, Ethical, and Study Oversight Considerations ................................................ 50  
10.1.1  Informed Consent Process  .............................................................................................. 50  
[IP_ADDRESS]  Consent/Assent and Other Informational Documents Provided To 
Participants  ................................................................................................................ 50  
[IP_ADDRESS]  Consent Procedures and Documentation  ................................................................ [ADDRESS_743823] Keepi[INVESTIGATOR_007]  .............................................................................. 53  
[IP_ADDRESS]  Data Collection and Management Responsibilities ................................................ 53  
[IP_ADDRESS]  Study Records Retention  ........................................................................................... [ADDRESS_743824] Policy  ............................................................................................... 55  
10.2  Additional Considerations  .................................................................................................... 55  
10.2.1  Research Related Injuries  ............................................................................................... 55  
10.3  Protocol Amendment History  ............................................................................................... 55  
11 References  ................................................................................................................................... 57  
12 Appendix  ..................................................................................................................................... 61  
12.1  Schedule of Activities (SoA)  .................................................................................................. 61  
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 5 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
12.2  Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric 
Adve rse Events, Corrected version 2.1 (July 2017) ............................................................ 62  
 
Table of Tables  
Table 1: National Early Warning Score (NEWS) ........................................................................... 35  
Table 2: Venipuncture Volumes1 ..................................................................................................... 36  
Table 3: Probability of detecting zero individuals or at least one individual with an 
Adverse Event (AE) for a variety of different underlying AE rates and sample size N =50 ....................................................................................................................................... 45
 
Table 4: Schedule of Activities  .......................................................................................................... [ADDRESS_743825]  
ECMO  extra corporeal membrane oxygenation  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
GLP  Good Laboratory Practice  
GMP  Good Manufacturing Practice  
HIV human immunodeficiency virus  
IB Investigator’s Brochure  
ICH The International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use  
IND Investigational New Drug Application  
IRB institutional review board  
ISBT  International Society of Blood Transfusion  
IVIG  intravenous immune globulin  
JAMA  Journal of the American Medical Association  
LIP Licensed Individual Practi tioner 
MMWR  Morbidity and Mortality Weekly Report  
MN microneutralization  
NAT  nucleic acid testing  
OTC  over the counter  
PCR  polymerase chain reaction  
PK pharmacokinetic  
RSV  respi[INVESTIGATOR_566218] -related acute lung injury  
VIG vaccinia immune globulin  
 
  
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 7 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
1 STUDY SUMMARY  
1.1 Synopsis  
Title:  An Open -Label, Single arm, Phase 1, Safety and Exploratory Efficacy Study 
of Convalescent Plasma for Severely Ill Mechanically Ventilated  Participants 
with COVID -19 Caused by [CONTACT_7544]-CoV-2 
Short Title:  COVID-19 Convalescent Plasma for Mechanically V entilated  Population 
Study 
Description :  This open- label, single arm, phase [ADDRESS_743826] of care. Participants will be assessed daily while hospi[INVESTIGATOR_566219] 15, 22, 29, and 60. All participants will undergo a series of safety, efficacy, and laboratory assessments.  Blood samples will be collected on Days 1 (prior to plasma administration), 3, 5, 8, 11, 15, 29, and 60. Oropharyngeal or endotracheal samples will be collected on Days 1 (prior to plasma administration), 3, 5, 8, 11, and 15. 
Objectives:  Primary Objectives  
The overall  objective of the study is to evaluate the safety and explore the 
efficacy of treatment with convalescent plasma in severely ill, mechanically ventilated participants w ith confirmed COVID- 19 disease.  
Secondary Objectives  
For the secondary objectives, we wi ll compare clinical severity between our 
intervention of convalescent plasma administration to matched participants in the placebo arm of the ongoing NIH study “DMID Protocol Number: 20-0006: A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospi[INVESTIGATOR_566220]”.  
Primary Endpoint:  The primary safety objective will be assessed by [CONTACT_566259] i ncidence of 
serious adverse events (SAEs) at Study Day 29. 
The primary efficacy objective will be assessed by [CONTACT_566260], as measured by [CONTACT_566261] . 
  
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 9 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
o National Early Warning 
Score (NEWS):  
 Time to discharge or to a NEWS  
of ≤ [ADDRESS_743827]  
 Change from Day 1 to Days 3, 5,  
8, 11, 15, and 29 in  NEWS  
  
 
o NEWS assessed daily while 
hospi[INVESTIGATOR_119818] 15 and 29. 
o Oxygenation:  
 Oxygenation free days to Day 29. 
 Incidence and duration of new 
oxygen use during the  study.   
• Days of supplemental oxygen  (if 
applicable)  
o Non-invasive 
ventilation/high  flow 
oxygen:  
 Non-invasive 
ventilation/high  flow 
oxygen - free days to Day  
29. 
 Incidence and 
duration of new non- 
invasive ventilation or high flow oxygen 
use during the  study.   
 
• Days of non- invasive 
ventilation (if applicable).  
• Days of high flow oxygen (if  
applicable).  
o Invasive Mechanical 
Ventilation / 
extracorporeal 
membrane oxygenation 
(ECMO):  
 Ventilator / ECMO free days  to 
Day 29. 
 Incidence and duration of new 
mechanical ventilation or ECMO 
use during the  study.  
  
 
• Days of invasive mechanical 
ventilation (if  applicable).  
• Days of ECMO (if applicable).  
 Hospi[INVESTIGATOR_059] 
o Duration of 
hospi[INVESTIGATOR_059].   
 Days of  hospi[INVESTIGATOR_059]  
 Mortality  
o 14-day mortality  
o 28-day mortality  
  
 Date and cause of death (if applicable)  
 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 10 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
2. Evaluate the safety of 
convalescent plasma administration 
as compared to placebo recipi[INVESTIGATOR_566221]: 20 -
0006by:  
 Cumulative incidence of Grade 3 and 4 
clinical and/or laboratory AEs through Day 29. 
 Changes in WBC with differential, hemoglobin, platelets,  creatinine, 
glucose, total bilirubin, ALT, AST, and PT over time (analysis of lab values in addition to AEs noted above).
 
  
 
• SAEs  
• Grade 3 and 4 AEs  
• WBC with differential, hemoglobin, platelets, creatinine, glucose, total bilirubin, ALT, AST, and PT on Day 1; Days 3, 5, 8, and 11 (while hospi[INVESTIGATOR_057]); and Days 15 and 29 (if lab collection is possible).
 
 
  
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 12 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
Evaluate the virologic efficacy of 
convalescent plasma as assessed by:  
o Percent of participants 
with detectable SARS-CoV -2 in OP or ET 
samples at Days 3, 5, 8, 11, or 15. 
o Quantitative SARS-
CoV -2 in OP or ET 
samples at Days 3, 5, 8, 
11, and 15. 
o Qualitative SARS-
CoV -2 in OP or ET 
samples at Days 3, 5, 8, 
11, and 15.  
 Quantitative and Qualitative PCR 
for SARS -CoV -2 in OP or ET swab 
at Day 1; Days 3, 5, 8, 11, and 15.  
 
Evaluate the timing and titer of anti -
SARS -CoV -2 antibody responses after 
convalescent plasma administration   Plasma antibody binding and 
neutralization on Day 1; Days 3,  8, 
15, 29, and 60  
Evaluate the timing and quality of 
SARS -CoV -2 cellular responses after 
convalescent plasma administration   Cellular responses in whole blood on 
Day 1; Days 3,  8, 15 29, and 60  
Evaluate the change in inflammatory 
responses with convalescent plasma administration  
  Evaluate the change in clinical status 
(by 8 -point ordinal scale and/or 
NEWS) with change in inflammatory 
markers  
  Plasma and cellular markers of 
inflammation on Day 1; Days 3, 8, 15, 29, and 60
 
 
 Ferritin, C Reactive Protein, D -
Dimer, Fibrinogen, Erythrocyte Sedimentation Rate, Triglycerides, IL-6 on Study Day 1, 3, 5, 8, 11, 15, 
29, and 60  (when available).
 
 
 
Study Population:  Hospi[INVESTIGATOR_057], intubated, mechanically ventilated  adults >18 year s old with 
COVID-19 pneumonia 
Phase:  Phase I  
Enrolling Sites : This is a single site study  conducted in the Hospi[INVESTIGATOR_566222]. 
Description of 
Study Intervention:  This single arm study will assess the administration of [ADDRESS_743828] recovered from 
COVID-19.  Participants will receive convalescent plasma on Study Day 1 in addition to standar d of care  
Study Duration:  We expect the study to last 6 months from initiation  
Participant Duration: An individual participant will complete the study in about 60 days, from screening at Day -1 or 1 to follow-up on Day 60 ± 5 days 
 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 14 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
2 INTRODUCTION AND RATIONAL E 
2.1 Study Rationale  
Coronavirus disease (COVID-19), the syndrome caused by [CONTACT_7544]-CoV-2, causes significant morbidity 
and mortality in a subset of infected individuals. In the most severely affected individuals, COVID-19 causes pneumonia and acute respi[INVESTIGATOR_1505] (ARDS) requiring mechanical ventilation. There are currently no effective biomedical therapi[INVESTIGATOR_55328], beyond supportive therapy, to treat COVID-19. Convalescent plasma from individuals who have recovered from COVID-19 may cont ain 
high titer anti- SARS -CoV -2 neutralizing antibodies that could help treat the disease. 
2.2 Background  
2.2.1  COVID -19 
Emerging infectious diseases can be defined as “infections that have newly appeared in a population or have existed previously but are rapi[INVESTIGATOR_566223].” [ 1, 2]  Over the 
last decade there has been an increase in recognized emerging or re-emerging infectious diseases.  This includes, but is not limited to Nipah virus, Lassa virus, Hantavirus, Hendra virus, West Nile virus, avian influenza, severe acute respi[INVESTIGATOR_7686] (SARS), Middle Eastern respi[INVESTIGATOR_7686] (MERS), and COVID-[ADDRESS_743829] recognized in a cluster of 
pneumonia cases in Wuhan, China in late 2019 [ 37]. Since then, COVID-19 has rapi[INVESTIGATOR_566224] a 
pandemic of unprecedented scope.  As of April 1, 2020, COVID-19 had infected over a million 
individuals and resulted in more than 50,000 deaths worldwide (JHU CRS site).  In the [LOCATION_002], the COVID -19 epi[INVESTIGATOR_566225], with more than 200,000 diagnosed infections and 
more than 5,000 deaths (JHU CRS site). 
COVID-[ADDRESS_743830] of care therapi[INVESTIGATOR_566226] (Cheng J, EJCMID 2003).  The convalescent plasma was obtained from SAR S 
patients who were afebrile for at least 7 days and 14 days from initial presentation. Of the 80 SARS-infected study participants receiving plasma, 33 experienced a study-defined “good outcome” by [CONTACT_566262] 22 days from plasma administration. More frequent good outcomes 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 15 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
were seen in participants receiving plasma early (within 14 days of presentation) and before 
development of SARS antibodies. Importantly, no immediate adverse events were noted.  
For COVID -19, there have been two rec ently published case series  describing a total of [ADDRESS_743831] publication, Shen  and colleagues described five critically 
ill COVID-19 patients with laboratory- confirmed disease, acute respi[INVESTIGATOR_1505] (ARDS) 
on mechanical ventilation, and high viral loads, who received plasma between day 10 and 22 of 
hospi[INVESTIGATOR_059].  All five participants experienced clinical improvement after plasma administration, with improvement in respi[INVESTIGATOR_566227] [ 25].  
The second report describes ten severely ill participants who received 1 unit of COVID-19 convalescent plasma between day 10 and 20 of symptomatic disease  [26].  Of the ten plasma 
recipi[INVESTIGATOR_840], three were supported by [CONTACT_566263], five were receiving high- or low- flow 
supplemental oxygen, while two were not receiving supplemental oxygen. After plasma administration, clinic al disease generally improved in terms of required oxygen support, lung imaging, 
and lab abnormalities, including leukopenia and some inflammatory markers.  Importantly, there were no serious adverse events in either report.  Although these trials are both small and uncontrolled, they describe generally safe and positive clinical responses to COVID -19 convalescent plasma 
administration.  
2.2.3  Passive Immunotherapy in Other Viral Infection 
A number of viral diseases are treated with antibody preparations with variable results.  These antibody preparations can be given as either convalescent plasma or intravenous immunoglobulin (IVIG). Curative treatment with IVIG is rare.  Red blood cell aplasia caused by [CONTACT_566264] B19 infection is the only recognized viral infect ion in which treatment with IVIG may eradicate the infection.  [ 3, 4] 
However, there is considerable evidence that immune globulin preparations may modify the natural history of viral diseases. These are summari zed below. 
• Influenza: Passive immunotherapy with convalescent plasma has been studied in many contexts against various strains of influenza.  A cohort study of patients with severe H1N1 2009 disease in Hong Kong compared outcomes in patients who received c onvalescent 
plasma with those who declined enrollment to the study, demonstrating a lower mortality in the plasma recipi[INVESTIGATOR_840]  [32].  A multicenter, prospective, double-blind, randomized t rial of 
H1N1 2009-immune plasma formulated into immunoglobulin, H-IVIG vs. normal IVIG.  H-IVIG treatment was associated with significantly lower [ADDRESS_743832]- treatment viral 
loads [ 34]. Recently, a large [LOCATION_002] multi-center, double-blinded trial of high- titer vs. 
low-titer anti-influenza plasma in individuals with severe influenza A.  The high- titer 
plasmas conferred no significant clinical benefit over the non- immune plasmas  [33]. 
• Cytomegalovirus (CMV): CMV enriched immune globulin preparations have shown benefit when used in combination with ganciclovir in the treatment of CMV pneumonia. [ 5]  
This immune globulin preparation is also utilized in the treatment of ganciclovir -resistant 
CMV infections.  
• Respi[INVESTIGATOR_14250] (RSV): In adult bone marrow transplant (BMT) patients with RSV pneumonia, combination therapy using aerosolized ribavirin and standard IVIG (500 mg/kg every other day for 12 days) for the treatment had a 22% mortality rate, compared to a historical mortality rate of 70%. [ 6] In pediatric BMT patients with RSV pneumonia, 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 16 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
patients treated with combination aerosolized ribavirin and RSV antibody enriched IVIG 
(Respi[INVESTIGATOR_566228]®) had a 9.1% mortality, compared with a historical 50-70% mortality rate of such patients given ribavirin alone. [ 7] 
• Vaccinia Virus: Certain complications of vaccination with the vaccinia virus (smallpox vaccine) are treated with vaccinia immune globulin (VIG). These included generalized vaccinia,  eczema vaccinatum, and progressive vaccinia. There have been no controlled 
trials of the efficacy of VIG. However, anecdotal experience suggests that treatment with VIG for these conditions is beneficial, and is now considered the standard of care. [ 8] 
• Hepatitis A: IVIG has also been shown useful in hepatitis A. Persons who have been recently exposed to hepatitis A and who have not been previously vaccinated with hepatitis A are recommended to receive standard IVIG as post -exposure prophylaxis. This is based 
on data that showed IVIG, when administered within 2 weeks following an exposure to hepatitis A, is greater  than 85% effective in preventing hepatitis A. [ 9] IVIG can also 
attenuate the clinical expression of hepatitis A infection when given later in the incubation period. [ 10] Standard IVIG is used because it does contain sufficient anti- hepatitis A 
antibodies.  
• Hepatitis B : For patients with hepatitis B and cirrhosis undergoing orthotopic liver 
transplant, hepatitis B hyperimmune IgG is given pre-operatively and post-operatively to prevent reinfection with hepatitis B. This has been shown to be 50-85% effective in preventing recurrence of hepatitis B in the transplanted liver. [ 11, 12] This effi cacy may be 
improved with the concurrent use of the antiviral lamivudine. [ 12] 
• Rabies: Rabies hyperimmune IgG is the standard recommended therapy after exposure to 
the rabies virus/rabid animal. [ 13] 
• Argentine Hemorrhagic Fever: Convalescent plasma from survivors is the standard of care 
and has been shown to reduce mortality from 50% to 4% if therapy is initiated within 8 days after disease onset. [ 14] 
 
2.3 Risk/Benefit Assessment  
2.3.1  Known Potential Risks  
[IP_ADDRESS]  Risk of Plasma Transfusions  
Common risks of plasma transfusions may include one or more of the following: fever, rash, hives, or 
headache. Other more serious risks are rare and may include the following: serious allergic reactions including anaphylaxis, bacterial infections, or viral infections like hepatitis B, hepatitis C, and human immunodeficiency virus (HIV).  
Transfusion-related acute lung injury (TRALI) may occur, but this risk is minimized by [CONTACT_566265]-HLA class I and class II antibodies in this study. TRALI is characterized by a clinical constellation of symptoms including dyspnea, hypotension and fever. Although the precise pathogenesis of TRALI remains unknown, it has been shown to be related to the transfusion of anti-HLA class I and anti -neutrophil antibodies most often from plasma from multiparous women 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 17 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
(antibodies presumably generated during pregnancy) or donors who have received multiple blood 
transfusi ons though the introduction of universal leukoreduction of blood products has largely 
mitigated the production of HLA antibodies in response to transfusion. The risk of TRALI was reported as [ADDRESS_743833]. [ 15] 
The infused plasma volume of 2 units is roughly 500 mL, so there is the risk of volume overload in the recipi[INVESTIGATOR_841], which could cause pulmonary edema. Participants with preexisting conditions who may not tolerate this volume of plasma will be excluded from this study, but this condition could still occur in recipi[INVESTIGATOR_840].  
There is also a possible increased risk of thrombotic events associated with plasma transfusion in severely -ill patients.  This has been reported in cancer, trauma, and surgical patients [ 38, 39, 40, 41].  It 
is possible that an increased risk of thrombotic events, including deep vein thrombosis or pulmonary embolism, could accompany plasma administration in severely- ill patients.  There are case reports of 
pulmonary emboli occurring after administration of IVIG and plasma therapy, though definitive studies assessing risk are lacking. [ 16] In one series [ADDRESS_743834] pulmonary emboli. [ 17] This high percentage has not been shown in other H1N1 series, 
and pulmonary emboli have been shown to develop in approximately 10- 15% of critically ill adults. 
[18] However, the potential risk of pulmonary embolism exists. 
[IP_ADDRESS]  Risk of Antibody -Mediated Enhancement (ADE) of Infection  
There is a theoretical risk that the antibodies within convalescent plasma could enhance SARS -CoV-[ADDRESS_743835] between two related viral strains  (e.g., Dengue infection) or weak or non-neutralizing 
antibodies (HIV- 1) [27], [28].  We have seen minimal virus evo lution, to date, in the COVID-[ADDRESS_743836] not suggested enhanced infection ( Hung IF  (see 
above)) [ 25].  Continued study and assessment for ADE is warranted. 
 
[IP_ADDRESS]  Risk of Antibody -Mediated Acute Lung Injury  
There is a theoretical risk of antibody-mediated acute lung injury with convalescent plasma 
administration.  Antibody-mediated acute lung injury has been repo rted in a nonhuman primate model 
of SARS -CoV-1 [ 42].  In this study, rhesus macaques with anti- SARS -CoV-1 antibodies via active or 
passive immunization, demonstrated pro- inflammatory lun g responses during acute SARS infection.  
This phenomenon has not been reported in the observational reports of convalescent plasma administration in either SARS -CoV-1 or COVID- 19, but remains a theoretical concern, especially in 
plasma administration during acute or early infection.   
 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 18 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
[IP_ADDRESS]  Risk of Decreased Protective Immunity  
Immune responses to past Coronavirus diseases, including SARS and MERS, have been shown to be 
transient and directly related to the severity of illness.  Patients with asymptomatic or mild disease had lower titer and less durable markers of immunity, including antibody responses [ 29].  Mechanistically, 
antibody-based therapy aims to neutralize and/or clear virus, leading to less antigen for immune recognition and response maturation. Thus, it is possible that modifying the course of disease and decreasing viral antigen burden could hamper the duration or magnitude of protective immune responses after COVD -[ADDRESS_743837] should be further investigated, and 
convalescent plasma- treated individuals considered for enhanced vaccination strategies, as they are 
developed.  The risk of decreased protective immunity is outweighed in moderately and severely individuals requiring hospi[INVESTIGATOR_5478]/or ventilation, for whom the immediate risks of disease are more substantial.  
[IP_ADDRESS]  Risk of Plasma Transfusions Interaction with Immunization  
The Advisory Committee on Immunization Practices (ACIP) advises that people who r eceive plasma 
products wait 7 months (assuming they receive 10 mL/kg) from administration of the plasma before receiving the measles vaccine (given as MMR - mumps, measles and rubella) or the varicella 
(chickenpox) vaccine. This is because these are live v irus vaccines, and antibodies in the plasma may 
limit the immune response to the vaccine. Antibody-containing blood products do not interfere with the immune response to yellow fever vaccine and are not believed to interfere with the response to live typhoid, live attenuated influenza, rotavirus, or zoster vaccines.  While both varicella and zoster vaccines use an attenuated varicella virus, the zoster vaccines is at least 14 times greater amount of virus than that found in varicella vaccine explaining the difference in ACIP recommendations.  The amount of plasma administered in this study is 20-30% less than in the ACIP guidance (7-8 mL/kg for most participants), so the deferral period is likely slightly less (i.e., 5-6 months) [ 35]. 
In a separate document, ACIP stresses the importance of rubella and varicella immunity among women of child-bearing age and recommends “the postpartum vaccination of women without evidence of immunity to rubella or varicella with MMR, varicella, or MMRV vaccines should not be delayed because of receipt of anti -Rho(D) globulin or any other blood product during the last trimester of 
pregnancy or at delivery. These women should be vaccinated im mediately after  giving birth…” [ 36].  
While not explicitly stated, we assume this supersedes the deferral considerations above.  Attempts by [CONTACT_566266].  
[IP_ADDRESS]  Risk of Phlebotomy  
The primary risks of phlebotomy include local discomfort, occasional bleeding or bruising of the skin at the site of needle puncture, and rarely hematoma, infection, or fainting. At the time of enrollment and during study visits, each participant will be asked about participation in other research studies to ensure that blood draws do not exceed the following amounts for all research protocols combined: 10.5 mL/kg or 550 mL, whichever is smaller, over any 8-week period for adults, and no more than 5 mL/kg may in a single day (no more than 9.5 mL/kg may be drawn over any 8- week period) f or persons under 
the age of 18. 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 19 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
[IP_ADDRESS]  Risk of Nasopharyngeal  Swab  
The primary risk of a nasal swab is local discomfort. Rarely, there can be local bleeding from the nasal 
mucosa, which is controlled with local measures such as pressure or packing with gauze. 
[IP_ADDRESS]  Risk of Oropharyngeal Swab  
The primary risk of an oropharyngeal swab is local discomfort. This swab can stimulate the gag reflex, 
and very rarely vomiting.  
[IP_ADDRESS]  Risk of Endotracheal Aspi[INVESTIGATOR_566229], and rarely can cause a small amount of bleeding. 
2.3.2  Known Potential Benefits  
[IP_ADDRESS]  Benefits of Treatment  
The benefits of antiviral treatment with convalescent immune plasma in  patients with severe COVID -
19 disease are unknown. However, it is possible (and it is the hypothesis), that convalescent plasma in 
addition to standard of care (i.e., supportive care and institutional and/or medical provider recommended therapi[INVESTIGATOR_014]) will mo re rapi[INVESTIGATOR_566230], reduce the duration and severity 
of illness, reduce complications, and improve outcomes after infection with COVID-19 compared to not receiving convalescent plasma. 
[IP_ADDRESS]  Alternatives  
The alternative to participation in this study is routine standard of care, which can include 
supplemental oxygen, fluids, and other symptomatic treatments. Additional treatments for this type of participants may include experimental antivirals and/or immunomodulators (e.g., hydroxychloroquine) determined by [CONTACT_566267][INVESTIGATOR_566231]. 
2.3.[ADDRESS_743838] mortality rates up to 28% in hospi[INVESTIGATOR_566232] (REFS).  At this time, there are no 
effective COVID -[ADDRESS_743839] of care involves supportive therapy (e.g., oxygen, 
fluids), with consideration of a variety of unproven, experimental treatments (e.g., antivirals and immunomodulators). 
The administration of blood products, including plasma, is a common and well tolerated clinical option 
used in multiple indications. There are limited reports of the effects of convalescent plasma for COVID-19, with just two small observational studies describing a total of 15 patients, to date [ 25, 26 ].  
The experience from these studies and studies of convalescent plasma in other viral infections suggest that plasma administration is safe and well tolerated and  may con fer clinical benefit.  Thus, for severe 
COVID-19 disease, the possible therapeutic benefit of convalescent plasma outweighs the minimal safety risks.  
 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 20 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
[IP_ADDRESS]  Assessment of Potential Risks and Benefits in Pregnant Individuals  
[IP_ADDRESS].1 Rationale for inclusion of Pregnant Women in COVID- 19 clinical research  
There is growing consensus on the ethical and practical need to more proactively consider inclusion of 
pregnant women in clinical research, including in COVID-19 studies [ 47.]. Formal studies provide 
evidence -based guidance on treatment options for application in medically compromised pregnancies. 
The supervision of the patient and the quality of the data acquired in formal, preferably controlled, 
studies are superior to that received in the post-marketing environment.  Safety and efficacy information will be obtained sooner and with fewer pregnant women and fetuses exposed than if the drug information is obtained following its release on the market (recognizing, as with all drugs, that some objectives cannot be met until widespread use occurs).  
In particular, advocacy groups recommend that pregnant women should be included in clinical 
research when participation in a study provides potential therapeutic benefit and the anticipated benefits exceed the anticipated risks and when their exclusion cannot be justified by [CONTACT_13120] 
[48]. 
 
[IP_ADDRESS].[ADDRESS_743840] of care and is used frequently for 
several conditions, including massive bleeding or coagulation disorders, as described in clinical society 
guidelines, (eg, the British Royal College of Obstetrics and Gynaecologists) [49]. Further, the use of antibody preparations, like IVIG, are used commonly to treat autoimmune or coagulation disorders and to protect the fetus from maternal antibody disorders [ 43, 44, 45, 46]. The known risks of plasma 
infusion, including TRALI and volume overload complications discussed above for all populations, remain are issues for pregnant women, but have not been reported in higher frequency or severity.  Given the frequent and generally safe experience with plasma administration and the potential benefit of plasma in severe- disease, administra tion of convalescent plasma can be regarded as a reasonable 
strategy to evaluate.  
 
 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 21 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
3 STUDY OBJECTIVES AND ENDPOINTS  
3.1 Primary Objective s 
The overall objective of the study is to evaluate the safety and explore the efficacy of treatment with 
convalescent plasm a in severely ill hospi[INVESTIGATOR_363012] -19 disease.  
The primary safety objective will be assessed by [CONTACT_287157] (SAEs) at Study Day 29.  
The primary efficacy objective will be assessed by [CONTACT_566268] . 
 
3.2 Secondary Objectives and Endpoints  
 
OBJECTIVES  ENDPOINTS (OUTCOME MEASURES)  
1. Evaluate the clinical efficacy of  convalescent plasma 
administration as compared to placebo recipi[INVESTIGATOR_566233]: 20 -0006  
• Clinical Severity  
o Ordinal  scale:  
 Time to an improvement of one category and two categories  from Day 1 using an 
ordinal  scale. 
 Participant clinical status using ordinal scale at Days 3, 5, 8, 11,15, 22, and 29. 
 Mean change in the ordinal scale from Day 1 to Days 3, 5, 8, 11, 15, 22, and  29.  
 
 
 
• Clinical outcome assessed using ordinal scale daily while hospi[INVESTIGATOR_435618] 15, 22, and 29. 
• Clinical status assessment (8 -point ordinal scale) 
includes:  
1. Not hospi[INVESTIGATOR_057], no limitations on activities.  
2. Not hospi[INVESTIGATOR_057], limitation on activities and/or 
requiring home oxygen;  
3. Hospi[INVESTIGATOR_057], not requiring supplemental 
oxygen - no longer requires ongoing medical care;  
4. Hospi[INVESTIGATOR_057], not requiring supplemental 
oxygen - requiring ongoing medical care (COVID -
19 related or otherwise);  
5. Hospi[INVESTIGATOR_057], requiring supplemental oxygen;  
6. Hospi[INVESTIGATOR_057], on non- invasive ventilation or 
high flow oxygen devices;  
7. Hospi[INVESTIGATOR_057], on invasive mechanical 
ventilation or ECMO; 
8. Death  
 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 22 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
OBJECTIVES  ENDPOINTS (OUTCOME MEASURES)  
o National Early Warning Score (NEWS):  
 Time to discharge or to a NEWS  of ≤ [ADDRESS_743841]  
 Change from Day 1 to Days 3, 5,  8, 11, 15, and 
29 in NEWS.   
 
• NEWS assessed daily while hospi[INVESTIGATOR_566234] 15 and  29. 
o Oxygenation:  
 Oxygenation free days to Day 29. 
 Incidence and duration of new oxygen use during 
the study.   
 Days of supplemental oxygen  (if applicable)  
o Non-invasive ventilation/high  flow oxygen:  
 Non-invasive ventilation/high  flow oxygen - 
free days to Day  29. 
• Incidence and duration of new non - 
invasive ventilation or high flow oxygen use during the  study.   
 
• Days of non- invasive ventilation (if 
applicable).  
• Days of high flow oxygen (if  applicable).  
o Invasive Mechanical Ventilation / extracorporeal 
membrane  oxygenation (ECMO):  
 Ventilator / ECMO free days  to Day  29. 
 Incidence and duration of new mechanical ventilation or ECMO use 
during the  study.   
 
• Days of invasive mechanical ventilation (if  
applicable).  
• Days of ECMO (if applicable).  
• Hospi[INVESTIGATOR_059] 
o Duration of hospi[INVESTIGATOR_059].   
• Days of  hospi[INVESTIGATOR_059]  
• Mortality  
o 14-day mortality  
o 28-day mortality   
• Date and cause of death (if applicable)  
2. Evaluate the safety of convalescent plasma 
administration as compared to matched participants from the control arm of DMID Protocol No. 20- 0006 
by: 
• Cumulative incidence of Grade 3 and 4 clinical 
and/or laboratory AEs through Day 29. 
• Changes in WBC with differential, hemoglobin, platelets,  creatinine, glucose, total bilirubin, ALT, 
AST, and PT over time (analysis of lab values in addition to AEs noted above).   
 
• SAEs  
• Grade 3 and 4 AEs  
• WBC with differential, hemoglobin, platelets, creatinine, glucose, total bilirubin, ALT, AST, and PT on Day 1; Days 3, 5, 8, and 11 (while hospi[INVESTIGATOR_057]); and Days 15 and 29 (if attends in- person visit or still 
hospi[INVESTIGATOR_057]).  
 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 23 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
3.3 E xploratory  Objectives and Endpoints  
 
OBJECTIVES  ENDPOINTS (OUTCOME MEASURES)  
Exploratory   
Evaluate the clinical efficacy of  convalescent plasma 
administration as compared to active drug ( e.g., 
Remdesivir) recipi[INVESTIGATOR_566221]: 
20-0006  
• Clinical Severity  
o Ordinal  scale:  
 Time to an improvement of one category and two categories  from Day 1 using an 
ordinal  scale. 
 Participant clinical status using ordinal scale at Days 3, 5, 8, 11,15, 22, and 29. 
 Mean change in the ordinal scale from Day 1 
to Days 3, 5, 8, 11, 15, 22, and  29.  
 
 
 
• Clinical outcome assessed using ordinal scale daily while hospi[INVESTIGATOR_435618] 15, 22, and 29. 
o National Early Warning Score (NEWS):  
 Time to discharge or to a NEWS  of ≤ [ADDRESS_743842]  
 Change from Day 1 to Days 3, 5,  8, 11, 
15, and 29 in  NEWS.   
 NEWS assessed daily while hospi[INVESTIGATOR_119818] 15 
and 29. 
o Oxygenation:  
 Oxygenation free days to Day 29. 
 Incidence and duration of new oxygen use 
during the  study.   
Days of supplemental oxygen  (if applicable)  
o Non-invasive ventilation/high  flow 
oxygen:  
 Non-invasive ventilation/high  flow oxygen 
- free days to Day  29. 
 Incidence and duration of new non - 
invasive ventilation or high flow oxygen 
use during the  study.   
 
• Days of non- invasive ventilation (if 
applicable).  
• Days of high flow oxygen (if  applicable).  
 
o Invasive Mechanical Ventilation / 
extracorporeal membrane  oxygenation 
(ECMO):  
 Ventilator / ECMO free days  to Day  
29. 
 Incidence and duration of new mechanical ventilation or ECMO use 
during the  study.   
 
• Days of invasive mechanical ventilation (if  
applicable).  
• Days of ECMO (if applicable).  
 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 24 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
OBJECTIVES  ENDPOINTS (OUTCOME MEASURES)  
Evaluate the virologic efficacy of convalescent plasma 
as assessed by:  
• Percent of participants with detectable SARS -CoV -2 
in OP or ET samples at Days 3, 5, 8, 11, and 15.  
• Quantitative SARS- CoV -2 in OP or ET samples at 
Days 3, 5, 8, 11, and 15.  
• Qualitative SARS- CoV -2 in OP or ET samples at 
Days 3, 5, 8, 11, and 15.  • Quantitative and Qualitative PCR for SARS -CoV -2 
in OP or ET swab at Day 1; Days 3, 5, 8, and 11 
(while hospi[INVESTIGATOR_057]) and Days 15, if available.  
Evaluate the timing and titer of anti-SARS -CoV -2 
antibody responses after convalescent plasma administration
 • Plasma antibody binding and neutralization on Day 1 
(prior to plasma administration); Days 3, 8, 15, 29, and visit Day 60.  
Evaluate the timing and quality of SARS -CoV -2 
cellular r esponses after convalescent plasma 
administration  • Cellular responses in whole blood on Day 1(prior to 
plasma administration); Days 3, 8, 15, 29, and visit Day 60. 
Evaluate the change in inflammatory responses with 
convalescent plasma administration  • Plasma  and cellular markers of inflammation on Day 
1(prior to plasma administration); Days 3, 8, 15, 29, and visit Day 60.  
Evaluate the change in clinical status (by 8 -point 
ordinal scale and/or NEWS with change in inflammatory markers
 • Ferritin, C Reactive Protein, D -Dimer, Fibrinogen, 
Erythrocyte Sedimentation Rate, Triglycerides, IL -6 
on Study Day 1, 3, 5, 8, 11, 15, 29 (when available).  
Cumulative incidence of serious adverse events by 
[CONTACT_4475] 60  • SAEs  
 
Evaluate the safety of convalescent plasma 
administration as compared to active drug ( e.g., 
Remdesivir) recipi[INVESTIGATOR_566221]: 20-0006  
• Cumulative incidence of Grade 3 and 4 clinical 
and/or laboratory AEs through Day 29. 
• Changes in WBC with differential, hemoglobin, platelets,  creatinine, glucose, total bilirubin, 
ALT, AST, and PT over time (analysis of lab values in addition to AEs noted above).
  
 
• SAEs  
• Grade 3 and 4 AEs  
• WBC with differential, hemoglobin, platelets, creatinine, glucose, total bilirubin, ALT, AST, and PT on Day 1; Days 3, 5, 8, and 11 (while 
hospi[INVESTIGATOR_057]); and Days 15 and 29 (if attends in-
person visit or still hospi[INVESTIGATOR_057]).  
 
 
  
Protocol PennCCP -[ADDRESS_743843] of adults >[ADDRESS_743844] of care. Participants will be assessed daily while 
hospi[INVESTIGATOR_566235] 29 days.  Participants discharged from the hospi[INVESTIGATOR_566236] 15, 22, 29, and 60. The Study Day 22 visit may be conducted by [CONTACT_648]. All participants will undergo a series of safety, efficacy, and laboratory assessments.  Blood samples will be collected on Days 1 (prior to plasma administration), 3, 5, 8, 11, 15, 29, and 60. Oropharyngeal or endotracheal samples will be collected as possible on Days 1 (prior to plasma administration), 3, 5, 8, 11, and 15. Given the COVID-[ADDRESS_743845] of treatment with COVID -19 convalescent 
plasma in severely ill, mechanically ventilated COVID -19 patients.  Given the severity of disease in 
this population and the limited treatment options available, the study will not include a placebo arm. For evaluation purposes, we will compare endpoints in these participants with matched participants 
from the placebo arm of the ongoing NIH study: DMID Protocol Number: 20-0006: A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID -19 in Hospi[INVESTIGATOR_566237].  
4.2 Scientific Rationale for Study Design  
Given the severity of illness in mechanically ventilated patients with COVID -19 pneumonia and the 
lack of effective therapeutics, we will not include a placebo arm.  As a single arm stu dy, the primary 
safety and efficacy outcomes will be descriptive.  As secondary objectives, we will compare our intervention of convalescent plasma administration to matched participants in the placebo arm of the ongoing NIH study “DMID Protocol Number: 20-0006: A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID -19 in Hospi[INVESTIGATOR_566220]”. 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 26 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
4.3 Justification for Dose  
Plasma volume in adults can be estimated by [CONTACT_265927] 40 
mL/kg. [ 19] For 70-kg person, the plasma volume would be estimated to be 2800 mL (40 mL/kg x70 
kg). 
Standard plasma dosing is 2 units, (~200-250 mL per unit).  At the discretion of the principal 
investigator, patients less than 90kg or with concern for volume overload, may receive 1 unit of plasma.  
The volume of a unit of plasma is 200-300 mL). Therefore, the study dose of 2 units of plasma could 
be equal to as much as  500 mL. A plasma volume of 500 mL at an anti- SARS -CoV-2 titer of 1:160 
would increase the titer in  the plasma to approximately 1:25; then fall to 1:[ADDRESS_743846] recovered from COVID-19 is not fully 
characterized; in the recently described cohort of 5 patients receiving convalescent plasma, anti -SARS -
CoV-2 titers ranged from 1:1,800 to 16,200 by [CONTACT_566269], and 1:80 to 1:480 to neutralizin g antibody (Shen JAMA 2020). A second observational description of convalescent 
plasma in China identified ten donors. In their cohort of 40 plasma donors, 39 had neutralizing antibody titers >1:160, while a single donor had titers of 1:32, as determined by [CONTACT_566270] (Duan PNAS 2020). 
In Influenza studies, Rockman et al demonstrated in a H5N1 model in ferrets, that achieving a HI titer 
of 1:8 with a hyperimmune IVIG without any other antivirals was sufficient in preventing death if given early in the illness (during fever), and in delaying death if given at the onset of severe disease. [20] 
4.[ADDRESS_743847] completed the study if he or she has completed all phases of the study including the Day 60 visit shown in the Schedule of Activities (SoA), Appendix 12.1. Given the COVID-[ADDRESS_743848] left the hospi[INVESTIGATOR_307], the collection of Day 60 data for primary and secondary endpoints and the collection of Day 60 samples for exploratory tests may be performed up to 90 days following the Day 60 visit. 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 27 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
5 STUDY POPULATION 
5.1 Inclusion Criteria  
1. Adult ≥18 years of age  
2. Laboratory-confirmed SARS-CoV-2 infection as determined by [CONTACT_566271] 72 hours prior to 
enrollment.  
Note – An exception must be requested to the Sponsor if ≥[ADDRESS_743849] . 
3. Hospit alized, on invasive mechanical ventilat ion or ECMO , consistent with a clinical 
status assessment 8-point ordinal scale severity score of 7 .  
4. Documentation of pneumonia with radiographic evidence of infiltrates by [CONTACT_9661] (e.g., chest x -ray or CT scan).  
5. Patient or proxy is willing and able to provide written informed consent and comply 
with all protocol requirements . 
 
5.2 Exclusion Criteria  
1. Contraindication to transfusion (e.g., severe volume overload, history of severe allergic 
reaction to blood products), as judged by [CONTACT_093]. 
2. Clinical suspi[INVESTIGATOR_515535] (acute decompensation) is primarily due to a condition other than COVID-19 
3. Receipt  of other investigational therapy as a part of another clinical trial .   
a. Note : investigational therapi[INVESTIGATOR_566238], (eg, remdesivir, 
hydroxychloroquine) are permissible .  
 
 
5.[ADDRESS_743850] been completed, the investigator or designee is to review the 
inclusion/exclusion criteria and determine the participant’s eligibility for the study.  
Only the reason(s) for ineligibility will be collected on screen failures. Participants  who are found to be 
ineligible will be told the reason(s) for ineligibility.  
Individuals who do not meet the criteria for participation in this study (screen failure) because of an abnormal laboratory finding may be rescreened once.  
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 28 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
5.5 Strategies  for Recruitment and Retention  
5.5.1  Recruitment  
Screening will begin with a brief discussion with study staff. If both studies are open to enrollment, 
information about both PennCCP-01 and PennCCP-02 will be provided to all potential participants and or legally authorized representative.  Information regarding the risks and benefits and scientific aims of the single arm study PennCCP-01 and the randomized, controlled study PennCCP-02 will be presented. Questions will be asked to determine potential eligibility. Screening procedures can begin only after informed consent is obtained by a Study Investigator. 
5.5.2  Retention  
Retention of participants in this trial is very important for determining the primary endpoint. As such, 
after hospi[INVESTIGATOR_2345], participants will be reminded of subsequent study visits and every effort will be made to accommodate the participant’s schedule to facilitate follow -up within the specified visit 
window. Additionally, there are many circumstances that influence the ability to obtain outcome 
information after discharge. Follow-up visits may be conducted by [CONTACT_119916]-person visits are not feasible.  Data and samples may be collected from subject’s hom e, office, or hospi[INVESTIGATOR_6042]. 
5.5.[ADDRESS_743851] to participants for the research tests, procedures/evaluations and study product while taking part in this trial. Procedures and treatment for clinical care including costs associated with hospi[INVESTIGATOR_566239], participant’s insurance or third party. 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 29 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
6 STUDY INTERVENTION 
6.1 Study Intervention(s) Administration  
6.1.[ADDRESS_743852] care plus 2 units of COVID-19 convalescent plasma on Study Day 1.  
Participants will receive plasma compatible with their blood type (per standard blood bank practice ). 
6.1.[ADDRESS_743853] occurs during infusion, 
the infusion may be slowed temporarily or permanently discontinued, as deemed appropriate by [CONTACT_093]. As a guide, local side effects (e.g., infusion site burning),  nonallergic systemic effects (e.g., chills), and mild allergic reactions (itching, hives) can generally be alleviated by [CONTACT_532852], whereas serious allergic side effects (e.g., wheezing, hypotension) should result in the cessation of study plasma infusion. The treating investigator is ultimately responsible for making the decision to slow or stop study plasma infusion. If the infusion is discontinued, the participant should be treated according to best available local practices and procedures, and the Principal Investigator [INVESTIGATOR_566240]. Reason(s) for premature discontinuation of any plasma infusion must be documented in the medical record (source document) and on the CRF. 
As with any foreign protein, allergic reactions to dose administration are possible. Therefore, 
appropriate drugs such as Benadryl® and epi[INVESTIGATOR_566241] a cute allergic 
reactions must be immediately available, and study personnel must be trained to recognize and treat allergic reactions. If generalized urticaria, hypotension, or anaphylaxis occurs, the infusion of plasma should be immediately discontinued. T reatment should be given in an appropriate timeframe as 
medically indicated.  
All participants will be observed for at least [ADDRESS_743854] available local practices and procedures.  
6.2 Preparation/Handling/Storage/Accountability  
6.2.[ADDRESS_743855] will be stored in the HUP Stem Cell Laboratory until it is released to the PI [INVESTIGATOR_566242]. 
6.2.3  Preparation  
Preparation: Frozen product will be transported from the HUP Stem Cell Laboratory back to the HUP 
Blood Bank to be thawed before issuing to the patient’s transfusion team. 
6.3 Measures to Minimize Bias: Randomization and Blinding  
Not applicable. 6.4 Study Intervention Compliance  
Not applicable.  
6.5 Concomitant Therapy  
Participants will be monitored throughout the study for use of concomitant medications. Any 
prescription medications including IVIG, blood products, over-the-counter (OTC) preparations, herbal remedies, and/or nutritional supplements taken during the study period must be recorded on the CRF. 
It is also anticipated that participants may be treated with antibacterial agents, either for concomitant 
infection, or bacterial superinfection. The final decision for antibiotics (need, drug[s] and dose) and other medications will be made by [CONTACT_1963] (except as noted below under Prohibited Medications).  
6.5.1  Rescue Medicine  
Not applicable. 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 31 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
7 STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL 
Participants will be considered to have completed the study if they are followed through Study Day 60 
(+90 days) and complete the final study visit (or followed through to death at or before 60 days). 
7.1 Discontinuation of Study Intervention  
Participants (or their legal surrogates if participa nts become unable to make informed decisions) can 
terminate study participation at any time without prejudice. If a participant terminates participation 
before completing the study, the reason for this decision will be recorded in the CRF. Participants who withdraw from the study will not be replaced. 
Participants who indicate interest in withdrawing from the study should also be asked permission to be 
contact[CONTACT_218907] 2 9 and Day 60 (+90 days) by [CONTACT_566272] (date of discharge, disposition, 
and any adverse events that occurred during the study). This is not considered full withdrawal of consent, but the modified consent for limited follow-up should be noted in the medical record. 
Participants who fully withdraw consent will not be contact[CONTACT_23322].  
7.2 Participant Discontinuation/Withdrawal from the Study  
The investigator also has the right to withdraw participants from the study. Participants may be 
withdrawn from the study for either of the following reasons: 
• The participant is lost to follow -up. 
• The investigator believes that continuation in the study would be detrimental to the participant. 
 
If appropriate, the participant should not be fully withdrawn but rather have limited further study 
interventions. This limited follow -up would entail contact[CONTACT_566273] 29 by [CONTACT_566274] (date of discharge, disposition, and any AEs that occurred during the study). The reason for withdrawal from the study is to be recorded on the CRF.  
If a non -serious AE is unresolved at the time of discontinuation, efforts should be made to follow up 
until the event resolves or stabilizes, the participant is lost to follow -up, or there is some other 
resolution of the event. The investigator is to make every attempt to follow all SAEs to resolution. 
7.[ADDRESS_743856] two documented telephone calls and one written letter.  
Any participant withdrawn from the study will not be replaced.  
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 32 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
8 STUDY  ASSESSMENT AND PROCEDURES 
8.1 Efficacy Assessments 
For all efficacy assessments and follow-up visits, refer to SoA ( Table 4 ) for procedure to be done, and 
details below for each assessment.  
8.1.1  Screening Proc edures  
After the informed consent, some or all of the following assessments are performed to determine 
eligibility requirements as specified in the inclusion and exclusion criteria:  
• Confirm the positive SARS-CoV- [ADDRESS_743857] result.  
o If the original sample was >[ADDRESS_743858] 
be requested to the Sponsor. 
• Take a focused medical history, including the following information: 
o Day of onset of COVID-[ADDRESS_743859] on the appropriate CRF. 
• Women of childbearing potential should be counseled to either practice abstinence or use at 
least one primary form of contraception from  screening through Day 60. 
o Acceptable forms of contraception include barrier methods, copper or hormonal IUDs, 
implantable hormonal contraception, or oral contraceptives.  
o Note: If a woman is either po stmenopausal (i.e., has had ≥12 months of spontaneous 
amenorrhea) or surgically sterile (i.e., has had a hysterectomy, bilateral ovariectomy (oophorectomy), or bilateral tubal ligation), she is not considered to be of childbearing potential 
• Obtain height and weight (height can be self-reported) 
• Review results of recent radiographic imaging (x-ray or CT scan) 
• Perform a targeted physical exam focused on lung auscultation 
• Check a SpO2  
• Obtain blood for laboratory evaluations if not done as part of routine clini cal care in the 
preceding 48 hours: 
• Type and Screen  
• Study participants who qualify will be considered eligible. 
 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 33 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
The volume of venous blood to be collected is presented in Table 2 . 
 
[IP_ADDRESS]  Screening Procedures in Pregnant Women  
To best understand risk and benefit of study enrollment for pregnant women, we will follow this SOP 
for consideration of enrollment. 
Standard  Operating  Procedure for Pregnant Patients : 
1. Maternal  Fetal  Medicine (Obstetrical  service managing pregnant patients ) consults Infectious 
Diseases   
2. Obstetrics  (OB) and  Infectious Diseases  (ID) study physicians discuss possible enrollment in  
study, considering factors  including fetal  gestational  age,  maternal  co-morbidities,  severity  of 
COVID-19 disease,  volume status.   
3. Discussion  between  OB,  ID, patient  (if possible) and patient  legally  authorized  representative 
on risks  and benefits  of study.  
4. With  enrollment and  plasma  administration: close observation in  acute setting  (eg, in COVID -
19 unit, ICU  or Labor & Delivery)  
5. Continue close monitoring after  plasma  administration . Participants  will be followed through 
the 60 days of the study. Data will not be collected  after  the Day 60 visit nor will data be 
collected  on neonates.  
 
8.1.2  Measures of clinical support, limitations and infection control  
On each study day while hospi[INVESTIGATOR_566243] 29, the following measures for the previous 
day will be recorded. i.e., on Day 3, Day 2 measures are assessed as occurring anytime in that 24 hour period (00.00 to 23.59h):  
• Hospi[INVESTIGATOR_059]  
• Oxygen requirement 
• Non-invasive mechanical ventilation (via mask) requirement  
• High flow oxygen requirement. 
• Invasive mechanical ventilation (via endotracheal tube or tracheostomy tube) requirement.  
• ECMO requirement.  
• Ongoing medical care preventing hos pi[INVESTIGATOR_2345] (COVID -19 related or other medical 
conditions) 
• Limitations of physical activity (self -assessed).  
• Isolated for infection control purpose 
 
If drawn for clinical care, record inflammatory markers, including: 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 34 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
• Ferritin, C Reactive Protein, D-Dimer, Fibrinogen, Erythrocyte Sedimentation Rate, 
Triglycerides, IL -6. 
If and when a participant is discharged from the hospi[INVESTIGATOR_307], they will continue with study visits as an outpatient, for all Study Days that are applicable, including Days 15, [ADDRESS_743860] assessment of a given study day. 
From the measures collected in [IP_ADDRESS], this ordinal scale can be constructed.  
The scale used in this study is as foll ows:  
1. Not hospi[INVESTIGATOR_057], no limitations on activities  
2. Not hospi[INVESTIGATOR_057], limitation on activities and/or requiring home oxygen; 
3. Hospi[INVESTIGATOR_057], not requiring supplemental oxygen - no longer requires ongoing medical 
care;  
This would include those kept in hospi[INVESTIGATOR_41348]/infection control, awaiting bed in rehabilitation facility or homecare, etc.  
4. Hospi[INVESTIGATOR_057], not requiring supplemental oxygen - requiring ongoing medical care (COVID -19 related or otherwise);  
5. Hospi[INVESTIGATOR_057], requiring supplemental oxygen; 
6. Hospi[INVESTIGATOR_057], on non-invasive ventilation or high flow oxygen devices; 
7. Hospi[INVESTIGATOR_057], on invasive mechanical ventilation or ECMO; 
8. Death;  
 
By [CONTACT_566275], alternative scales can be constructed. 
8.1.4  National Early Warning Score (NEWS)  
NEWS has demonstrated an ability to discriminate participants at risk of poor outcomes . (Smith, 
2016). This score is based on 7 clinical parameters (see Table 1 ). The NEWS is being used as an 
efficacy measure. This should be evaluated at the first assessment of a given study day and prior to 
administration of study product. The [ADDRESS_743861] measurement prior to the time of assessment and a numeric score given for each parameter (e.g., a 
RR of 9 is one point, oxygen saturation of 92 is two points). This is recorded for the day obtained. i.e., on Day 3, Day 3 score is obtained and recorded as Day 3. 
Table 1: National Early Warning Score (NEWS)  
 
Level of consciousness = alert (A), and arousable only to voice (V) or pain (P), and unresponsive (U). 
 
8.[ADDRESS_743862] their utility in a 
treatment study. These are hypothesis generating and will not be submitted as part of a final CSR. 
8.3 Safety and Other Assessments  
Study procedures are specified in the SOA. A study physician licensed to make medical diagnoses and 
listed on the 1572 will be responsible for all trial- related medical decisions.  

 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 36 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
• Physical examination : A symptom- directed (targeted) physical examination will be 
performed at screening and when needed to evaluate possible adverse event(s) (i.e. any new 
symptoms). No physical exam is needed for routine study visits. 
• Clinical laboratory evaluations : 
• Fasting is not required before collection of laboratory samples. 
• Blood will be collected at the time points indicated in the SOA. Clinical laboratory parameters include WBC, differential, Hgb, PLT, Creatinine, glucose, total bilirubin, AST, ALT, and PT.  
• This testing will be performed at each clinical trial site in real time.  
 
Table 2: Venipuncture Volumes
1 
 Screen  Baseline         
Day +/ - Window  - 1 to 1  - 1 to 1  3±1 5±1 8±1 11±1  15±2  29±2  60±53 
Type and screen  X 
10mL          
Safety hematology, 
chemistry, liver tests   X 
10 mL  X 
10 mL  X 
10 mL  X 
10 mL  X 
10 mL  X 
10 mL  X 
10 mL   
Blood for plasma/  
serum and cells, including research assays   
X 
[ADDRESS_743863] Values 
or Abnormal Clinical Findings  
If a physiologic parameter (e.g., vital signs, or laboratory value) is outside of the protocol- specified 
range, then the measurement may be repeated once if, in the judgment of the investigator, the abnormality is the result of an acute, short- term, rapi[INVESTIGATOR_566244]. A 
physiologic parameter may also be repeated if there is a technical problem with the measurement caused by [CONTACT_566276] (i.e., inappropriate- sized BP cuff).  
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 37 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
8.4 Adverse Events and Serious Adverse Events  
8.4.1  Definition of Adverse Events (AE)  
AE means any untoward medical occurrence associated with the use of an intervention in humans, 
whether or not considered intervention-related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of medicinal (investigational) product.  
Any medical condition that is present at the time that the participant is screened will be considered as baseline and not reported as an AE. However, if the severity of any pre-existing medical condition increases, it should be recorded as an AE. 
Given the nature of severity of the underlying illness, participants will have many symptoms and 
abnormalities in vital signs and laboratory values. All Grade 3 and 4 AEs will be captured as AEs in this trial.  
8.4.2  Definition of Serious Adverse Events (SAE)  
A SAE is defined as “An AE or suspected adverse reaction is considered serious if, in the view of either the investigator or the Sponsor, it results in any of the following outcomes: 
• Death;  
• A life -threatening AE; 
• Inpatient hospi[INVESTIGATOR_1081]; 
• A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life fun ctions; or 
• A congenital anomaly/birth defect. 
 
Important medical events that may not result in death, be life -threatening, or require hospi[INVESTIGATOR_6721], based upon appropriate medical judgment, they may jeopardize the 
participa nt and may require medical or surgical intervention to prevent one of the outcomes listed in 
this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias, convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse. 
“Life- threatening” refers to an AE that at occurrence represents an immediate risk of death to a 
participant. An event that may cause death if it  occurs in a more severe form is not considered life- 
threatening. Similarly, a hospi[INVESTIGATOR_178105] a SAE. All SAEs, as with any AE, will be assessed for severity and relationship to study intervention by [CONTACT_1268] [INVESTIGATOR_566245]-investigator and will be recorded on the appropriate CRF. 
All SAEs will be followed through resolution or stabilization by [CONTACT_079] [INVESTIGATOR_566245]-investigator. 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 38 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
8.4.3  Classification of an Adverse Event  
The determination of seriousness, severity, and causality will be made by [CONTACT_079] [INVESTIGATOR_566246]-Investigator upon medical judgment. Qualified sub-investigator includes but is not limited to physicians, physician assistants, and nurse prac titioners.  
[IP_ADDRESS]  Severity of Event  
All AEs and SAEs will be assessed for severity, according to the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, version 2.1 (July 2017) (see Appendix 12.2). 
For AEs not included in the protocol defined grading system, the following guidelines will be used to 
describe severity.  
• Mild (Grade 1) : Events that are usually transient and may require only minimal or no 
treatment or therapeutic intervention and generally do not interfere with the participant’s usual activities of daily living.  
• Moderate (Grade 2) : Events that are usually alleviated with additional specific thera peutic 
intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research participant. 
• Severe (Grade 3) : Events interrupt usual activities of daily living, or significantly affects 
clinical status, or may require intensive therapeutic intervention. Severe events are usually incapacitating.  
• Severe (Grade 4) : Events that are potentially life threatening.  
 
AEs characterized as intermittent require documentation of onset and duration of each epi[INVESTIGATOR_1865]. The 
start and stop dates (duration) of each reported AE will be recorded on the appropriate CRF. Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each level of intensity.  
[IP_ADDRESS]  Relationship to Study Intervention  
For each reported adverse reaction, the PI [INVESTIGATOR_566247]: 
All adverse events (AEs) must have their relationship to the st udy intervention (product, process, 
and/or procedure) assessed by [CONTACT_10261]/her clinical judgment. The degree of certainty about causality will be graded using the categories below. In a clinical trial, the study product must always be considered. 
• Definitely Related – There is clear evidence to suggest a causal relationship, and other possible contributing factors can be ruled out. The clinical event, including an abnormal laboratory test result, occurs in a plausible time relationship to PCCP  administration and 
cannot be explained by [CONTACT_9153]. The response to withdrawal of the PCCP  (dechallenge) should be clinically plausible. The event must be 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 39 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
pharmacologically or phenomenologically definitive, with use of a satisfactory rechallenge 
procedure if necessary. 
• Probably Related – There is evidence to suggest a causal relationship, and the influence of other factors is unlikely. The clinical event, including an abnormal laboratory test result, occurs within a reasonable time after administration of the PCCP , is unlikely to be 
attributed to concurrent disease or other drugs or chemicals, and follows a clinically reasonable response on withdraw al (dechallenge). Rechallenge information is not required 
to fulfill this definition.  
• Possibly Related – There is some evidence to suggest a causal relationship (e.g., the event occurred within a reasonable time after administration of the trial medication ). However, 
other factors may have contributed to the event (e.g., the participant’s clinical condition, other concomitant events). Although an AE may rate only as “possibly related” soon after discovery, it can be flagged as requiring more information and later be upgraded to “probably related” or “definitely related”, as appropriate.  
• Unlikely to be related – A clinical event, including an abnormal laboratory test result, 
whose temporal relationship to PCCP  administration makes a causal relationship 
improbable (e.g., the event did not occur within a reasonable time after administration of 
the <study intervention>) and in which other drugs or chemicals or underlying disease 
provides plausible explanations (e.g., the participant’s clinical condition, other concomitant treatments).  
• Unrelated  – The AE is completely independent of PCCP  administration, and/or evidence 
exists that the event is definitely related to another etiology. There must be an alternative, definitive etiology documented by [CONTACT_15370]. 
 
[IP_ADDRESS]  Exp ectedness  
The Principal Investigator [INVESTIGATOR_21190] (AE) is 
expected or unexpected. An AE will be considered unexpected if the nature, severity, or frequency of the event is not consistent with the risk information previously described for the study intervention. 
8.4.4  Time Period and Frequency for Event Assessment and Follow -Up 
Safety will be assessed by [CONTACT_566277] (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, version 2.1 (July 2017 at each study visit. Participants will be monitore d by [CONTACT_379224], physical 
examinations, and other studies. If the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, version 2.1 (July 2017) (See Appendix 12.2) grading does not exist for an adverse event, the severity of mild, moderate, severe, life-threatening, and death, corresponding to Grades 1-5, will be used whenever possible. 
At each contact [CONTACT_6635] , the investigator will seek information on adverse events by [CONTACT_105]-
directive questioning and, as appropriate, by [CONTACT_5148]. Adverse events may also be detected when 
they are volunteered by [CONTACT_566278], or through 
 
  
Protocol PennCCP -[ADDRESS_743864], or other assessments. Information on all adverse events will be 
recorded in the source documentation. To the extent possible, adverse events will be recorded as a diagnosis and symptoms used to make the diagnosis recorded within the diagnosis event. If the AE is a 
laboratory abnormality that is part of a clinical condition or syndrome, it should be recorded as the syndrome or diagnosis rather than the individual laboratory abnormality. 
As much as possible, each adverse event or follow-up information will be evaluated to determine: 
1. Severity grade ( DAIDS Table for Grading the Severity of Adult and Pediatric Adverse 
Events, Corrected version 2.1 (July 2017) . See Appendix 12.2. 
2. Duration (start and end dates) 
3. Relationship to the study treatment or process – [Reasonable possibility that AE is 
related: No (unrelated/ not suspected) or Yes (a suspected adverse reaction)]. If yes (suspected) - is the  event possibly, probably or definitely related to the investigational 
treatment?  
4. Expectedness to study treatment or process – [Unexpected – if the event severity and/or frequency is not described in the investigator brochure (if applicable) or protocol]. 
5. Action taken with respect to study or investigational treatment or process (none, dose adjusted, temporarily interrupted, permanently discontinued, unknown, not applicable) 
6. Whether medication or therapy taken (no concomitant medication/non-drug therapy, concomitant medication/non -drug therapy) 
7. Whether the event is serious  
 
Once an adverse event is detected, it should be followed until its resolution or until it is judged to be 
permanent, and assessment should be made at each visit (or more frequently, if necessary) of any changes in severity, the suspected relationship to the study treatment, the interventions required to treat it, and the outcome. 
For this study, all Grade 3 and 4 AEs, all SAEs occurring from the time the informed consent is signed 
through the Day 60 visit will be documented, recorded, assessed, and reported. In addition, any grade 1 or 2 or higher hypersensitivity reaction is also reported as an AE. 
8.4.5  Adverse Event Reporting 
[IP_ADDRESS]  Reporting Period 
Adverse events will be reported from the time of informed consent until study completion. [IP_ADDRESS]  Investigator Reporting: Notifying the Study Sponsor  
Information on all AEs should be recorded on the appropriate CRF. 
Every SAE, regardless of suspected causality (e.g., relationship to study product(s) or study 
procedure(s) or disease progression) must be reported to the sponsor within [ADDRESS_743865] be reported to the Sponsor as 
a follow-up to the original epi[INVESTIGATOR_5319] 24 hours of the investigator receiving the follow-up information. A SAE considered completely unrelated to a previously reported one should be reported separately as a new event.  
Send the SAE report to the [EMAIL_10792] indicating the protocol number and the study product. 
New information regarding the SAE will be reported as it becomes available and in the same manner 
that the initial SAE (i.e. SAE form ). The investigator must follow the event to resolution or until the 
event is deemed and documented irreversible, whichever is longer. 
[IP_ADDRESS]  Investigator Reporting: Local Reporting Requirements  
The investigator will report AEs and SAEs to the  IRB/EC of record and other local regulatory groups 
per the local requirements.  
8.4.[ADDRESS_743866] include an assessment of whether there is a reasonable possibility that the Penn COVID-19 Convalescent Plasma caused the event. Study endpoints that are serious adverse events (e.g., all-cause mortality) must be reported in accordance with the protocol unless there is evidence suggesting a causal relationsh ip between the Penn COVID- 19 Convalescent Plasma and 
the event (e.g., death from anaphylaxis). In that case, the investigator must immediately report the event to the sponsor. 
New information regarding the SAE will be reported as it becomes available and in the same manner 
that the initial SAE (i.e. SAE form). All serious adverse events (SAEs) will be followed until satisfactory resolution or until the site investigator deems the event to be chronic or the participant is stable. Other supporting documentation of the event may be requested by [CONTACT_8704]. 
The SAE reports to the Sponsor should be sent to: [EMAIL_10792] indicating the 
protocol number and the study product 
The study sponsor will be responsible for notifying the Food and Drug Administration (FDA) of any 
unexpected fatal or life- threatening suspected adverse reaction per applicable regulations. In addition, 
the sponsor must notify the FDA , as applicable and all participating investigators of potential serious 
risks, from clinical trials or any other source, as per the applicable regulation. 
A S[LOCATION_003]R is any SAE where a causal relationship with the study product or process or procedure is at 
least reasonably possible but is not listed in the IB, Package Insert, and/or Summary of Product Characteristics  
8.4.[ADDRESS_743867] interfered with the effectiveness of a contraceptive medication or method. Pregnancy is not a contraindication to receipt of plasma transfusion and will not be reported or followed if not associated to an adverse event.  
8.5 Unanticipated Problems  
8.5.1  Definition of Unanticipated Problems (UP)  
The Office for Human Research Protections (OHRP) considers unanticipated problems involving risks to participan ts or others to include, in general, any incident, experience, or outcome that meets all  the 
following criteria:  
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures that are described in the protocol- related documents, s uch as the Institutional Review Board (IRB)-
approved research protocol and informed consent document; and (b) the characteristics of the participant population being studied; 
• Related or possibly related to participation in the research (“possibly related” means there is a reasonable possibility that the incident, experience, or outcome may have been caused by [CONTACT_3459]); and 
• Suggests that the research places participants or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized. 
 
UP are generally non -medical events, as medical events would be capture under AEs 
8.5.2  Unanticipated Problem Reporting 
Unanticipated problems ( UPs) such as:  
• Post-marketing withdrawal of a drug, device, or biologic used in a research protocol due to 
safety concerns.  
• FDA ban of a drug, device, or biologic used in a research protocol due to safety concerns. 
• Complaint of a participant when the complaint indicates unexpected risks, or the complaint 
cannot be resolved by [CONTACT_5051] 
• Breach of confidentiality  
• Incarceration of a participant when the research was not previously approved under Subpart C and the investigator believes it is in the best interest of the participant  to rema in on the study 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 43 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
• Premature closure of a study (e.g., due safety, lack of efficacy, feasibility, financial reasons, 
etc.) should be reported by [CONTACT_566279] (IRB). The UP report will include the following information: 
• Protocol identifying information: protocol title and number, PI’s name, and the IRB project number; 
• A detailed description of the event, incident, experience, or outcome;  
• An explanation of the basis for determining that the event, incident, experience, or outcome represents an UP;  
• A description of any changes to the protocol or other corrective actions that have been taken or are proposed in response to the UP. 
 
To satisfy the requirement for prompt reporting, UPs will be reported  using the following timeline: 
• UPs that are serious adverse events (SAEs) will be reported as any other SAE. 
• Any other UP will be reported to the Sponsor and  IRB within 3 days of the investigator 
becoming aware of the problem. 
 
8.5.3  Reporting Unanticipated Problems t o Participants  
The Sponsor does not plan to report adverse events to participants unless it is required by [CONTACT_5151], 
the IRB or FDA. 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 44 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
9 STATISTICAL CONSIDERATIONS  
9.1 Statistical Hypotheses 
Primary Safety Endpoints:  Cumulative incidence o f serious adverse events (SAEs), i.e. the 
proportion of individuals with at least one SAE, at Day 29. 
We hypothesize that [ADDRESS_743868] any related AE to happen relatively shortly after infusion but will assess the AE at all study timepoints. Overall SAE rates, those broken down by [CONTACT_6657]. Similar rates will be calculated from the matched placebo arm 
in DMID Protocol Number: 20-0006 in order to better understand the background rates of SAEs. 
Primary Efficacy Endpoint:  Time to clinical improvement, as me asured by [CONTACT_566280].  
In this one- arm trial, the efficacy analysis will be primarily descriptive. Cumulative incidence curves 
for time to removal from mechanical ventilation will be calculated, treating death as a competing 
event. If evaluable, the median time to removal from mechanical ventilation along with 95% 
confidenc e intervals will be calculated.  
Secondary Efficacy Endpoint(s):   Comparison of clinical severity between patients receiving 
convalescent plasma and a matched placebo arm from DMID Protocol Number: 20-0006. 
The key parameter of interest will be the comparison of clinical severity between individuals receiving 
the experimental intervention versus matched placebo individuals from DMID 20-006, as measured by a clinical severity score that takes into account both survival time and time to removal from mechanical ventilation  in a prioritized manner . The null hypothesis is that experimental individuals 
will have the same median severity as the matched placebo i ndividuals. The severity score is based on 
a procedure by [CONTACT_566281] 2016, which ranks all survivors better than non-survivors, individuals with shorter removal from ventilation times as better, and individuals with shorter times to death as worse.  This type of severity score, or prioritized outcome, has been advocated in many settings such as 
infectious disease and cardiovascular outcome settings [ 30]. This analysis will have more powe r to 
detect differences than looking only at one individual endpoint and can also take into account whether death follows a patient’s removal from mechanical ventilation, unlike an analysis of time to ventilation removal that treated death as censoring; ho wever, for interpretive purposes the log rank for time to 
removal from mechanical ventilation (treating death as censoring) and time to death will also be calculated.   The goal is to find good matched placebo participants for all individuals, and then the 
median severity will be compared with a Wilcoxon signed rank test. If good individual matching is not achievable, then the unpaired Peto- Peto Wilcoxon test statistic will be used to compare median 
severity. In the case of the unmatched analysis, Shaw and Fay [ADDRESS_743869] one dose of the experimental treatment. For efficacy endpoints, analyses will be according to the intent- to-treat principle and 
outcomes on all enrolled participants  will be included for analysis. All power calculations assume 
Type I error rate of alpha=0.05. Calculations were done using STATA/SE v16.0. 
With an overall sample size of 50, the expected probability of observing zero or at least one adverse 
event at varying underlying adverse event rates under a binomial distribution is shown below in Table 3. At this sample size, it is likely to see at least one adverse event even with relatively small rates of adverse reactions.  For example, 50 individuals combined across dose groups, there is close to an 80% chance of observing at least one individual with an event if the underlying AE rate is 3%. The analysis of AE rates will primarily be descriptive due to the la ck of power to make formal comparisons 
with the matched placebo group. For example, compared to a background AE rate of 0.02 in the matched placebo group, there would be 80% power to detect an AE rate of 20% or higher.  
Table 3: Probability of detecting zero individuals or at least one individual with an 
Adverse Event (AE) for a variety of different underlying AE rates and sample 
size N =50  
AE rate  Pr(0 events)  Pr(1+ event)  
0.001  0.95 0.05 
0.005  0.78 0.22 
0.01 0.61 0.39 
0.02 0.36 0.64 
0.03 0.22 0.78 
0.04 0.13 0.87 
0.05 0.08 0.92 
0.10 0.01 0.99 
 
While the sample size is driven by [CONTACT_566282], we also consider the operating characteristics 
of the proposed sample size for the analysis of the primary and secondary efficacy endpoints. The primary efficacy outcome is time to clinical improvement, as measured by [CONTACT_566261]. Cumulative incidence curves for time to removal from mechanical ventilation will be calculated, treating death as a competing event. If evaluable, the median time to removal from mechanical ventilation along with 95% confidence intervals will be calculated. We also consider the precision around the proportion of participants  that improved by [CONTACT_2006] 15. With 50 participants , there is 
about 85% power to reject a background rate of 30% or lower if the exper imental treatment is 
associated with a 50% or higher improvement rate at Day 15. Similarly, we will have about 83% power to reject a background rate of 50% or lower if the experimental treatment is associated with a 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 46 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
70% or higher improvement rate. Power calculations rely on the Pearson’s chi- squared test 
approximation. 
For the comparison of the secondary efficacy outcomes for the matched pair analysis with the DMID 
Protocol Number: 20-[ADDRESS_743870] the null hypothesis that there is a 50 -50 chance that the individuals receiving the experimental treatment had lower 
severity at Day 15 compared to the matched placebo individual. The analysis of the Win Ratio,  [31] 
which simply ranks the experimental participan t within each matched pair as either better or worse by 
[CONTACT_566283], if evaluable, and otherwise considers the patient ranking according to the time to going off mechanical ventilation, reduces to a simple binomial proportion. Thus, for [ADDRESS_743871] 82% power to reject the null proportion= 50% if the experimental treatment is associated with a 70% or higher improvement rate.  The proposed analysis for this endpoint, described in the previous section, is expected to have even better power by [CONTACT_566284] [ 30]. 
9.[ADDRESS_743872]- infusion safety data are available.  
The per -protocol (PP) analysis set comprises all participants  who received [ADDRESS_743873] enrolled in the study. 
9.4 Statistical Analyses  
9.4.1  General Approach  
Descriptive statistics (mean, standard deviation, minimum, med ian interquartile range, and maximum 
values for continuous variables; and frequencies and percentages for categorical variables) will be computed for all study variables for the above populations. Unless otherwise specified, a complete case analysis will b e considered such that missing values will not be replaced, and calculations will be done 
on available reported values. If there is a substantial amount of missing data we may consider imputation methods and adjust the analyses accordingly. Analyses will primarily be descriptive; estimates will be presented with 95% confidence intervals. Any significance testing will be done at the 0.05 level. Details for the primary and key secondary analyses are provided below. A formal Statistical Analysis Plan (SAP) will be developed prior to the conducting the comparative analysis with the matched placebo participants from DMID Protocol 20-0006. 
9.4.2  Analysis of the Primary Endpoint(s)  
The primary safety endpoint is cumulative incidence of serious adverse events (SAEs) at Day 29, 
calculated as the percent of individuals who had at least one SAE by [CONTACT_2006] 29. The SAE rate at all other time points of the study will also be calculated. The overall SAE incidence will be presented, as well as separately by [CONTACT_566285][INVESTIGATOR_14839]. Percentages will be based on the 
number of subjects who were treated. Additional frequencies will be presented with respect to maximum severity and to relationship to COVID19 and study product. Multiple occurrences of the 
 
  
Protocol PennCCP -[ADDRESS_743874]/COVID19.  
The primary efficacy endpoint is the cumulative incidence for time to removal from mechanical 
ventilation, which will be calculated using cumulative incidence curves that treat death as a competing 
event. If evaluable, the median time to removal from mechanical ventilation along with 95% confidence intervals will be calculated.  No formal hypothesis testing will be done for this endpoint; however, furt her analyses will be considered as part of the secondary endpoints.  
9.4.3  Analysis of the Secondary Endpoint(s)  
Analyses of secondary outcomes from this one- arm clinical trial will be primarily descriptive. 
Cumulative incidence curves will be considered for time- to-event endpoints par ticipant to death as a 
competing risk. Binary proportions will be estimated along with Clopper-Pearson 95% confidence intervals. Continuous endpoints will be summarized with means, SD and normal 95% confidence intervals. Ordinal endpoints (e.g. 8- point clinical severity score) will be summarized by [CONTACT_566286] 15, 22, and 29. 
For the comparison with placebo participants on DMID 20-006, we will consider a matched pair 
analysis, matching on sex, age, and mechanical ventilation at baseline. The key parameter of interest 
will be the comparison of clinical severity between individuals receiving the experimental intervention versus matched placebo individuals from DMID 20-006, a s measured by a clinical severity score that 
takes into account both survival time and time to removal from mechanical ventilation. The severity score is based on a procedure proposed by [CONTACT_566281] 2016, which ranks all survivors better than non-survivor s, individuals with shorter removal from ventilation times as better, and individuals with 
shorter times to death as worse. The goal is to find good matched placebo participants for all individuals, and then the analysis will be a comparison of severity within the matched pairs, using a Wilcoxon signed rank test. If good individual matching is not achievable, then the unpaired generalized logrank statistic will be used to compare median severity, according to the Shaw and Fay procedure which uses the bivari ate non -parametric MLE survival distribution to handle censoring for 
the clinical severity if necessary. In the case of the unmatched analysis, Shaw and Fay [ADDRESS_743875] differences than looking only at only an individual endpoint and can also take into account whether death follows a patient’ s removal from mechanical ventilation, unlike an analysis of time to 
ventilation removal that treated death as censoring; however, for interpretive purposes the log rank for time to removal from mechanical ventilation (treating death as censoring) and time  to death will also 
be calculated. Details for the statistical analysis of the comparison of these cohorts for other secondary endpoints will be provided in the SAP. 
9.4.4  Safety Analyses  
The primary outcome is cumulative incidence of SAE through day 29, as described in Section 9.4.2. 
Secondary and Exploratory Safety endpoints include death through Day 29, SAEs, discontinuation of study drug infusions, and Grade 3 and 4 AEs. Safety events will be analyzed as individual events and as part of a composite endpoint (e.g. any SAE). Proportions at specific study time points, e.g. Day 15, 22, [ADDRESS_743876] event for 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 48 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
the composite endpoint. Each AE will be counted once for a given participant and graded by [CONTACT_493336]-19 or study intervention. AEs will be coded using the current version of the Medical Dictionary for Regulatory Activities (MedDRA). AEs will be presented by [CONTACT_9313], duration (in days), start- and stop-date. Adverse events leading to premature discontinuation from the study intervention and serious treatment- emergent AEs will be summarized.  
Events that would result in immediate study pause for DSMB review and the potential stoppi[INVESTIGATOR_566248]: transfusion reactions or coagulopathic events. Plasma transfusion is a sa fe and 
commonly used treatment and so we do not anticipate additional SAE, above what these critically ill patients would experience as part of their baseline risk. 
9.4.[ADDRESS_743877] will be participant  
demographics, e.g. a ge, gender, race, as well as clinical and laboratory variables describing co -
morbidities and disease severity at baseline. P -values for significance testing between groups, e.g., 
Fisher’s exact test for proportions or Wilcoxon Rank Sum for continuous, will be considered but differences between groups inter preted primarily qualitatively.  
9.4.[ADDRESS_743878] (DSMB) will monitor ongoing results to ensure participant well -
being and safety as well as study integrity. The DSMB will be convened for a detailed review of safety data after [ADDRESS_743879], and then as needed. No formal statistical interim analyses are planned. Events that would result in immedia te study pause for DSMB review and the potential stoppi[INVESTIGATOR_566248]: transfusion 
reactions or coagulopathic events. Plasma transfusion is a safe and commonly used treatment and so we do not anticipate additional SAE, above what these critically ill patients would experience as part of their baseline risk. 
The study team will provide the DSMB Committee reports of enrollment, baseline characteristics, 
follow-up rates, and safety data. Data on matched placebo subjects from DMID-20-[ADDRESS_743880] ed to be available until after the study has reached full enrollment and so comparisons with this 
cohort and so the analysis comparing enrolled participants with this cohort will not be presented for DSMB review.  
9.4.7  Sub- Group Analyses  
Subgroup analyses for the primary and key secondary  efficacy outcomes will be considered to see 
where the differences between the matched placebo treatment varied across the following subgroups: age, sex, and duration of symptoms prior to enrollment. A forest plot will display confidence intervals across subgroups. We do not expect to have enough sample size to conduct formal interaction tests to determine whether the effect of treatment varies by [CONTACT_6496].  
 
  
Protocol PennCCP -[ADDRESS_743881] of 
evaluations are shown in the Schedule of Activities ( Appendix 12.1).  
9.4.9  Exploratory Analyses  
We will analyze a number of  biomarkers of immune response and virologic efficacy.  Binary 
proportions will be estimated along with Clopper-Pearson 95% confidence intervals. Continuous endpoints will be summarized with means, SD and normal 95% confidence intervals. Trends over time will be assessed descriptively, as well as with linear mixed effects models if appropriate. We will also 
consider the clinical efficacy of convalescent plasma administration as compared to active drug (e.g., Remdesivir ) recipi[INVESTIGATOR_566221]: 20-0006. Analysis of these comparative endpoints 
will be similar to that for the comparison of the study cohort with the matched placebo recipi[INVESTIGATOR_840], as described in Section 9.4.3. Further details will be provided in the SAP. 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 50 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  
10.1 Regulatory, Ethical, and Study Oversight Considerations  
10.1.1  Informed Consent Process  
[IP_ADDRESS]  Consent/Assent and Ot her Informational Documents Provided To Participants  
Consent forms describing in detail the Penn COVID-19 Convalescent Plasma, study procedures, and 
risks are given to the participant and written documentation of informed consent is required prior to starting the study intervention. 
[IP_ADDRESS]  Consent Procedures and Documentation  
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the study and continues throughout the individual’s study participation. Consent forms wil l be Institutional 
Review Board (IRB) -approved and the participant will be asked to read and review the document. The 
investigator will explain the research study to the participant or legally authorized representative (LAR) where appropriate,  and answer any questions that may arise. A verbal explanation will be 
provided in terms suited to the participant’s comprehension of the purposes, procedures, and potential risks of the study and of their rights as research participants. Participants /LAR  will have the  
opportunity to carefully review the written consent form and ask questions prior to signing. The participants /LAR  should have the opportunity to discuss the study with their family or surrogates or 
think about it prior to agreeing to participate. The participant will sign the informed consent , either 
electronically or wet ink signature [CONTACT_566292]. Participants must be informed that participation is voluntary and that they may withdraw from the study at any time, without prejudice. A copy of the informed consent document will be given to the participants for their records. To avoid paper and bio-contaminants, this will be done via electronic means.  The rights and welfare of the participants will be protected by [CONTACT_142321].  
If the participant is able to consent, the process will be done in person and documentation of the participant’s consent will be recorded electronically following the University of Pennsylvania IBB guidance. 
10.1.2  Study Discontinuation and Closure  
This study may be temporarily suspended or prematurely terminated by [CONTACT_282037] [INVESTIGATOR_566249] i s sufficient reasonable cause. Written notification, documenting the reason for study 
suspension or termination, will be provided by [CONTACT_21224], investigator, funding agency, the Investigational New Drug (IND), the sponsor and the FDA . If the study is prematurely terminated or suspended, the Principal Investigator (PI) will promptly 
inform study participants, the Institutional Review Board (IRB), and sponsor and will provide the reason(s) for the termination or suspension. Study participants will be contact[INVESTIGATOR_530], as applicable, and be informed of changes to study visit schedule. 
Circumstances that may warrant termination or suspension include, but are not limited to: 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 51 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
• Determination of unexpected, significant, or unacceptable risk to participants 
• Demonstration of efficacy that would warrant stoppi[INVESTIGATOR_007] 
• Insufficient compliance to protocol requirements 
• Data that are not sufficiently complete and/or evaluable 
• Determination tha t the primary endpoint has been met 
• Determination of futility  
 
Study may resume once concerns about safety, protocol compliance, and data quality are addressed, 
and satisfy the sponsor, IRB and/or Food and Drug Administration (FDA). 
In terminating the stud y, the Sponsor and the Principal Investigator [INVESTIGATOR_566250] ’ interests.  
10.1.[ADDRESS_743882] by [CONTACT_3486], their 
staff, and the sponsor(s) and their interventions. This confidentiality is extended to cover testing of biological samples and genetic tests in addi tion to the clinical information relating to participants. 
Therefore, the study protocol, documentation, data, and all other information generated will be held in strict confidence. No information concerning the study or the data will be released to any unauthorized third party without prior written approval of the sponsor. 
All research activities will be conducted in as private a setting as possible.  
The study monitor, other authorized representatives of the sponsor, representatives of the Institutional 
Review Board (IRB), regulatory agencies or pharmaceutical company supplying study product may 
inspect all documents and records required to be maintained by [CONTACT_093], including but not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study. The clinical study site will permit access to such records.  
The study participant’s contact [CONTACT_10414]. At the end of the study, all records will continue to be kept in a secure location for as long a period as dictated by [CONTACT_3488], Institutional policies, or sponsor requirements. 
10.1.4  Future Use of Stored Specimens and Data  
Secondary Human Participant Research is the re- use of identifiable data or identifiable biospecimens 
that were collected from some other ‘‘primary’’ or ‘‘initial’’ activity, such as the data and samples 
collected in this protocol. Any use of the sample or data for secondary research purposes, however, will be presented in a separate protocol and require separate IRB approval.  
Participants will be asked for consent to collect additional blood, the use of residual specimens, and samples for secondary research. Extra blood will be drawn for secondary research during each visit when a study blood samples are obtained. 
 
  
Protocol PennCCP -[ADDRESS_743883] participant’s 
confidentiality. Secondary research with coded samples and data may occur; however, participant confidentiality will be maintained as described for this protocol. An IRB review of the secondary research using coded specimens is required. 
Samples designated for secondary research use may be used for understanding the SARS-CoV-[ADDRESS_743884] benefits to the participant for extra specimens collected or from the secondary 
research. No results from secondary research will be entered into the partic ipant’s medical record. 
Incidental findings will not be shared with the participant, including medically actionable incidental findings, unless required by [CONTACT_2371]. 
Participants may withdraw permission to use samples for secondary use at any time by [CONTACT_566287]. If the participant subsequently changes his/her decision, the samples will be destroyed if the samples have not been used for research or released for a specific research project.  
10.1.[ADDRESS_743885] (DSMB) composed of individuals with the appropriate expertise. Members of the DSMB should be independent from the study conduct and free of conflict of interest, or measures should be in place to minimize perceived conflict of interest.  The DSMB will meet at least semiannually to assess safety and efficacy data on 
each arm of the study. The DSM B operates under the rules of an approved charter that is  written and 
reviewed at the organizational meeting of the DSMB. At this time, each data element that the DSMB needs to assess will be clearly defined. The DSMB will provide its input to the study sponsor.  
10.1.[ADDRESS_743886] of the trial is in compliance with the currently approved protocol/amendment(s), with International Council for 
Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice (ICH GCP), and with applicable regulatory requirement(s). 
• Monitoring for this study will be performed by [CONTACT_566288].  
• In an effort to ensure the safety of the study personnel and the monitors during the COVID-[ADDRESS_743887] as a consequence of the COVID- 19 pandemic are lifted . 
• The site should ensure that all safety related information is in an electronic record or  or scanned 
into a secure access application  that the monitor can access. Source data verification will be 
conducted between electronic record  and the sponsor EDC. 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 53 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
• The Sponsor will be provided copi[INVESTIGATOR_566251] . 
• Details of clinical site monitoring are documented in a Data Safety Monitoring Plan ( DSMP). 
The DS MP describes in detail who will conduct the monitoring, at what frequency monitoring 
will be done, at what level of detail monitoring will be performed, and the distribution of monitoring reports. The DSMP is written to allow non safety related items to be deferred to later visits if necessary and therefore some items may be deferred to a later visit that can be conducted in person. Close out visits will need a follow up in person visit, at a later date. 
• Independent audits  or compliance reviews  may be conducted by [CONTACT_566289] . 
 
10.1.7  Quality Assurance and Quality Control  
All monitoring and audits are to be performed according to ICH GCP E6(R2). 
Each clinical site will perform internal quality management of study conduct, data and biological 
specimen collection, documentation and completion. An individualized quality management plan will be developed to descri be a site’s quality management.  
Quality control (QC) procedures will be implemented beginning with the data entry system and data QC checks that will be run on the database will be generated. Any missing data or data anomalies will be communicated to the site(s) for clarification/resolution.  
Follow ing written Standard Operating Procedures (SOPs), the monitors will verify that the clinical trial 
is conducted and data are generated , and specimens are collected, documented (recorded), and reported 
in compliance with the protocol, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice (ICH GCP), and applicable regulatory requirements (e.g., Good Laboratory Practices (GLP), Good Manufacturing Practices (GMP)).  
The investigational site will provide direct access to all trial related sites, source data/documents, and reports for the purpose of monitoring and auditing by [CONTACT_456], and inspection by [CONTACT_3482]. 
10.1.[ADDRESS_743888] Keepi[INVESTIGATOR_007] 
[IP_ADDRESS]  Data Collection and Managem ent Responsibilities  
Source data are all information in original records (and certified copi[INVESTIGATOR_63062]) of clinical 
findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial. Source data should be attributable, legible, contemporaneous, original, accurate, and complete.  
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site investigator. The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data reported.  
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 54 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
Hardcopi[INVESTIGATOR_21193]. Data recorded in the electronic case report form (eCRF) derived from source documents should be consistent with the data recorded on the source documents. 
Clinical and laboratory data will be entered into a 21 CFR Part 11- compliant electronic data capture 
system (E DC) that includes individual user account level password protection. The EDC  used to 
support this trial is Penn CTMS (Velos version 9) which supports compliant eCRF collection, audit 
trail capabilities and facilitates source data verification . 
[IP_ADDRESS]  Study Records Retention  
Study related records, including the regulatory file, study product accountability records, consent forms, participant source documents and electronic records should be maintained until the Sponsor and provides notice 
10.1.9  Protocol Deviations  
The P I and the study team should document all scenarios where the protocol is not followed and 
provide, in particular: 
• Who deviated from the protocol 
• What was the deviation  
• When did the deviation occur 
• How did the deviation happen 
• What is the impact of the devi ation  
• A root cause analysis of why the deviation occurred 
 
If the assessment is determined to be of limited impact (minor deviation), the documentation for this 
assessment and the outcome should be reported to the Sponsor at the time of annual report. Reporting to the IRB should follow specific local requirements. 
If the assessment results in a determination that any of the following are potentially affected, the 
deviation would be considered of significant impact: 
• having the potential to advers ely affect participant  safety; OR  
• increases risks to participants; OR  
• adversely affects the integrity of the data; OR  
• violates the rights and welfare of participants, OR 
• affects the participant ’s willingn ess to participate in research.  
• there is a potential for an overall impact on the research that should be shared with the IRB for consideration and development of next best steps to address it 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 55 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
 
These scenarios should be reported to the Sponsor within 10 business days of discovery. Reporting to 
IRB should follow local requirements. 
10.1.10  Publication and Data Sharing Policy  
Following completion of the study, results of this research will be sent for publication in a scientific 
journal. As this is an adaptive study and given the public health urgency to diss eminate results, data 
from individual comparisons (i.e. the initial 2 study arms) can be published when those arms are fully enrolled and all participants in those arms are followed through to completion of the study. 
Data will be available immediately following publication, with no end date, with data sharing at the 
discretion of the Sponsor. Publication may occur prior to completion of a final clinical study report for the entire trial.  
Any publication, press release, and sharing of data for any reason must be shared with sponsor prior to release. 
The investigator is responsible for authoring a final clinical study report and sharing with the sponsor 
team. The Clinical Study Report will be issued within [ADDRESS_743889] of this trial. 
10.2 Additional Considerations  
10.2.1  Research Related  Injuries  
The PI [INVESTIGATOR_566252] . 
Immediate medical treatment may be provided by [CONTACT_16529], such as giving emergency 
medications to stop immediate allergic reactions. No financial compensation will be provided to the participant by [CONTACT_566290]. 
10.3 Protocol Amendment History  
 
Version  Date  Description of Change  Brief Rationale  
0.91 15-Apr-2020  • Original Version  •  
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 56 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
Version  Date  Description of Change  Brief Rationale  
2.0 24-Apr-2020  • Update eligibility criteria and study 
endpoints  
• Add rational for inclusion of pregnant women  
• Administrative changes  • To address IRB and FDA stipulations  
 
 
 
• For clarification purposes  
3.0 18- May-2020  • Review eligibility criteria to clarify investigational therapi[INVESTIGATOR_566253].  
• Add counsel to women of potential childbearing to avoid pregnancy 
• Add screening procedures in pregnant women  
• Administrative changes  • To address IRB stipulations  
  
 
 
 
 
• For clarification purposes  
4 28-Aug-2020  • Clarification of follow up time frame.  • For clarification purposes  
 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 57 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
11 REFERENCES 
1. Morse SS: Factors in the emergence of infectious diseases. Emerg Infect Dis 1995, 1(1):7-15. 
2. Bean WJ, Schell M, Katz J, Kawaoka Y, Naeve C, Gorman O, Webster RG: Evolution of the 
H3 influenza virus hemagglutinin from human and nonhuman hosts. J Virol 1992, 66(2):1129-1138. 3. Nour B, Green M, Michaels M, Reyes J, Tzakis A, Gartner JC, McLoughlin L, Starzl TE: 
Parvovirus B19 infection in pediatric transplant patients. Transplantation 1993, 56(4):835-838. 
4. Koduri PR, Kumapley R, Valladares J, Teter C: Chronic pure red cell aplasia caused by 
[CONTACT_566264] B19 in AIDS: use of intravenous immunoglobulin--a report of eight patients. Am J Hematol 1999, 61(1):16-20. 
5. Reed EC, Bowden RA, Dandliker PS, Lilleby [INVESTIGATOR_103117], Meyers JD: Treatment of cytomegalovirus 
pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988, 109(10):783-788. 
6. Whimbey E, Champlin RE, Englund JA, Mirza NQ, Pi[INVESTIGATOR_29358], Goodrich JM, Przepi[INVESTIGATOR_12776] D, 
Luna MA, Morice RC, Neumann JL et al: Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respi[INVESTIGATOR_566254]. Bone Marrow Transplant 1995, 16(3):393-399. 
7. DeVincenzo JP, Hirsch RL, Fuentes RJ, Top FH, Jr.: Respi[INVESTIGATOR_566255] - a compassionate use experience. Bone Marrow Transplant 2000, 25(2):161-165. 
8. Medical Management of Smallpox (Vaccinia) Vaccine Adverse Reactions: Vaccinia Immune 
Globulin and Cidofovir.  http://www.bt.cdc.gov/agent/smallpox/vaccination/mgmt- adv-reactions.asp   
9. Prevention of hepatitis A through active or passive immunization: Recommendations of the 
Advisory Committee on Immunization Practic es (ACIP). MMWR Recomm Rep 1999, 48(RR-12):1-
37. 
10. Kluge T: Gamma globulin in the prevention of viral hepatitis. A study on the effect of medium 
size doses. Rev Int Serv Sante Armees 1963, 36:Suppl 59-68. 
11. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H: Liver 
transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993, 329(25):1842-1847. 
12. Engler S, Sauer P, Klar E, Stremmel W, Kallinowski B: Prophylaxis of hepatitis B recurrence 
after liv er transplantation with lamivudin and hepatitis B immunoglobulin. Transplant Proc 2002, 
34(6):2285-2287. 
13. Human rabies prevention --[LOCATION_002], 1999. Recommendations of the Advisory Committee 
on Immunization Practices (ACIP). MMWR Recomm Rep 1999, 48( RR-1):1-21. 
14. Ruggiero HA, Perez Isquierdo F, Milani HA, Barri A, Val A, Maglio F, Astarloa L, Gonzalez 
Cambaceres C, Milani HL, Tallone JC: [Treatment of Argentine hemorrhagic fever with convalescent's plasma. 4433 cases]. Presse Med 1986, 15(45):2239-2242. 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 58 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
15. Bux J: Transfusion-related acute lung injury (TRALI): a serious adverse event of blood 
transfusion. Vox Sang 2005, 89(1):1-10. 
16. Alliot C, Rapin JP, Besson M, Bedjaoui F, Messouak D: Pulmonary embolism after 
intravenous immunoglobulin. J R Soc Med 2001, 94(4):187-188. 
17. Intensive-care patients with severe novel influenza A (H1N1) virus infection - Michigan, June 
2009. MMWR Morb Mortal Wkly Rep 2009, 58(27):749-752. 
18. Moser KM, LeMoine JR, Nachtwey FJ, Spragg RG: Deep venous thrombosis and pulmonary 
embolism. Frequency in a respi[INVESTIGATOR_265908]. Jama 1981, 246(13):1422-1424. 
19. Sekimoto M, Fukui M, Fujita K: Plasma volume estimation using indocyanine green with 
biexponential regression analysis of the decay curves. Anaesthesia 1997, 52(12):1166-1172. 
20. Rockman S, Maher D, Middleton D: The use of hyperimmune serum for severe influenza 
infections*. Crit Care Med 2012, 40(3):973-975. 
21. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li 
H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B: Clinical course and risk factors for mortality of adult inpatients with COVID -19 in Wuhan, China: a retrospective cohort study. Lancet  2020, 
395([ZIP_CODE]):1054-1062.  
22. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L: Epi[INVESTIGATOR_30092] 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet  2020, 395([ZIP_CODE]):507-513. 
23. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z: Clinical Characteristics of 138 Hospi[INVESTIGATOR_45077] 2019 Novel Coronavirus- Infected Pneumonia in Wuhan, China. JAMA  2020, 323(11):1061-1069. 
24. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS, for the China Medical Treatment Expert Group for Covid- 19: Clinical 
Characteristics of Coronavirus Disease 2019 in China. N Engl J Med  2020. doi: 
10.1056/NEJMoa2002032. 
25. Shen C, Wang Z , Zhao F , Yang Y, Li J , Yuan J, Wang F , Li D, Yang M, Xing L, Wei J , Xiao 
H, Yang Y, Qu J , Qing L, Chen L, Xu Z , Peng L, Li Y, Zheng H, Chen F , Huang K, Jiang Y, Liu D , 
Zhang Z, Liu Y , Liu L: Treatment of 5 Critically Ill Patients With COVID -19 With Convalescent 
Plasma. JAMA  2020. doi: 10.1001/jama.2020.4783. 
26. Duan  K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, Peng C, Yuan M, 
Huang J, Wang Z, Yu J, Gao X, Wang D, Yu X, Li L, Zhang J, Wu X, Li B, Xu Y, Chen W, Peng Y, 
Hu Y, Lin L, Liu X, Huang S, Zhou Z, Zhang L, Wang Y, Zhang Z, Deng K, Xia Z, Gong Q, Zhang W, Zheng X, Liu Y, Yang H, Zhou D, Yu D, Hou J, Shi Z, Chen S, Chen Z, Zhang X, Yang X: Effectiveness of convalescent plasma therapy in severe COVID -19 patients. Proc Natl Acad Sci U S A . 
2020, pii: 202004168. doi: 10.1073/pnas.[PHONE_5957]. 
27. Halstead SB: Pathogenesis of dengue: challenges to molecular biology. Science 1988, 
239(4839):476-81. 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 59 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
28. Takada A,  Kawaoka Y:  Antibody-dependent enhancement of viral infection: molecular 
mechanisms and in vivo implications. Rev Med  Virol . 2003, 13(6):387-98. 
29. Alshukairi AN, Khalid I, Ahmed WA, Dada AM, Bayumi DT, Malic LS, Althawadi S, Ignacio 
K, Alsalmi HS, Al -Abdely HM, Wali GY, Qushmaq IA, Alraddadi BM, Perlman S: Antibody 
Response and Disease Severity in Healthcare Worker MERS Survivors. Emerg Infect Dis  2016, 22(6).  
30. Shaw PA, Fay MP. A rank test for bivariate time‐to‐event outcomes when one event is a 
surrogate. Statistics in medicine  2016, 35(19):3413-23. 
31. Pocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. European heart journal  2012, 
33(2):176-82. 
32. Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, Liu R, Watt CL, Chan WM, Lai KY, 
Koo CK, Buckley T, Chow FL, Wong KK, Chan HS, Ching CK, Tang BS, Lau CC, Li IW, Liu SH, Chan KH, Lin CK, Yuen KY: Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) [ADDRESS_743890] Dis  2011, 52(4):447-56. 
33. Beigel JH, Aga E, Elie-Turenne MC, Cho J, Te bas P, Clark CL, Metcalf JP, Ozment C, 
Raviprakash K, Beeler J, Holley HP Jr, Warner S, Chorley C, Lane HC, Hughes MD, Davey RT Jr; IRC005 Study Team: Anti- influenza immune plasma for the treatment of patients with severe 
influenza A: a randomised, double-blind, phase 3 trial. Lancet Respir Med  2019, 7(11):941-950. 
34. Hung IFN, To KKW, Lee CK, Lee KL, Yan WW, Chan K, Chan WM, Ngai CW, Law KI, Chow FL, Liu R, Lai KY, Lau CCY, Liu SH, Chan KH, Lin CK, Yuen KY: Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest  2013, 144(2):464-473. 
35. CDC Yellow Book, Chapter 2, General Recommendations for Vaccination & Immunoprophylaxis : https://wwwnc.cdc.gov/travel/page/yellowbook-home-2014. 
36. MMWR Morb Mortal Wkly Rep. 2011 Jan 28;60(RR02):1-60. 
37. Huang Y, Cheng W, Zhao N, Qu H, Tian J: CT screening for early diagnosis of SARS-CoV-[ADDRESS_743891] Dis  2020 Mar 26. pii: S1473-3099(20)[ZIP_CODE]-3. doi: 10.1016/S1473-
3099(20)[ZIP_CODE]-3. [Epub ahead of print] 
38. Zander AL , Olson EJ, Van Gent JM , Bandle J , Calvo RY, Shackford SR, Peck KA , Sise CB , 
Sise MJ, King BS : Does resuscitation with plasma increase the risk of venous thromboembolism? J 
Trauma Acute Care Surg 2015 Jan;78(1):39-43. 39. Nilsson KR , Berenholtz SM , Garrett -Mayer E , Dorman T, Klag MJ, Pronovost PJ : Association 
between venous thromboembolism and perioperative allogeneic transfusion. Arch Surg 2007 
Feb;142(2):126-32. 
40. Gangireddy C, Rectenwald  J, Upchurch G, Wakefield  T, Khuri S, Henderson W, Henke P : Risk 
factors and clinical impact of postoperative symptomatic venous thromboembolism. Journal of 
Vascular Surgery  2007 Feb; 45(2):  341-342. 
 
  
Protocol PennCCP -[ADDRESS_743892]  S, Wilton  A, Lev  G, Sonoda Y, Hensley  M, Gemignani M, Barakat  
R, Chi D: Transfusion utilization during adnexal or peritoneal cancer surgery: Effects on symptomatic 
venous thromboembolism and survival. Gynecologic Oncology 2005; 99(2): 320-326. 
42. Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok H, Tang H, Nishiura K, Peng J, Tan Z, Wu T, 
Cheung KW, Chan KH, Alvarez X, Qin C, Lackner A, Perlman S, Yuen KY, Chen Z: Anti -spi[INVESTIGATOR_566256]-CoV infection. JCI 
Insight. 2019 Feb 21;4(4). pii: 123158.  
43. Winkelhorst D, Murphy MF, Greinacher A, Shehata N, Bakchoul T, Massey E, Baker J, 
Lieberman L, Tanael S, Hume H, Arnold DM, Baidya S, Bertrand G, Bussel J, Kjaer M, Kaplan C, Kjeldsen -Kragh J, Oepkes D, Ryan G: Antenatal management in fetal and neonatal alloimmune 
thrombocytopenia: a systematic review. Blood. 2017 Mar 16;129(11):1538-1547. 
44. Gamez J, Salvado M, Casellas M, Manrique S, Castillo F. Intravenous immunoglobulin as 
monotherapy for myasthenia gravis during pregnancy. J Neurol Sci. 2017;383:118–122. doi:10.1016/j.jns.2017.10.037 
 45. Winkelmann A, Rommer PS, Hecker M, Zettl [LOCATION_006]. Intravenous immunoglobulin treatment in 
multiple sclerosis: A prospective, rater -blinded analysis of relapse rates during pregnancy and the 
postnatal period. CNS Neurosci Ther. 2019;25(1):78–85. doi:10.1111/cns.[ADDRESS_743893] D, Murphy MF, Greinacher A, et al. Antenatal management in fetal and neonatal 
alloimmune thrombocytopenia: a systematic review. Blood. 2017;129(11):1538–1547. doi:10.1182/blood-2016-10-739656 
47. LaCourse S, John-Stewart G, Adams Waldorf K: Importance of inclusion of pregnant and 
breastfeeding women in COVID-19 therapeutic trials. Clinical Infectious Diseases. 2020, https://doi.org/10.1093/cid/ciaa444 
48. Shields, KE. Pregnancy and the Pharmaceutical Industry, Elsevier Press, 2019. 
https://www.nichd.nih.gov/sites/default/files/inline-f iles/Preg Women Clin Trials 2019.pdf  
49. Royal College of Obstetricians and Gynaecologists (2015), Blood Transfusion in Obstetrics  
(Guide No. 47). Retrieved from https://w ww.rcog.org.uk/globalassets/documents/guidelines/gtg-47.pdf  
 
 
  
Protocol PennCCP -01 - COVID -19 Convalescent Plasma for Mechanically Ventilated Population   
Penn COVID -19 Convalescent Plasma  Page 61 of 62 
 
 
Confidential and Proprietary Information of University of Pennsylvania  
 
12 APPENDIX 
12.1 Schedule of Activities (SoA)  
The following page outlines all of the assessments to be conducted during the study. A detailed 
presentation of assessments immediately follows the table. The day of enrollment is Study Day 1, the first day after enrollment is Study Day 2, etc. 
Table 4: Schedule of Activities  
 Screen  Baseline  Study Period  
 While hospi[INVESTIGATOR_566257] +/ - Window  −1 or 1  1 Day 2 to 29 if hospi[INVESTIGATOR_057]  157 ± 2 227 ± 3 297 ± 3 607 ± 510 
ELIGIBILITY         
Informed consent  X       
Demographics & Medical History  X       
Targeted physical exam  X       
Review SARS -CoV -2 results  X       
STUDY INTERVENTION         
Administration of investigational 
plasma   X      
STUDY PROCEDURES         
Vital signs including SpO 2  X4 Daily until discharge  or day 
29 of hospi[INVESTIGATOR_059]  X  X X 
Clinical data collection1  X4 Daily until discharge  or day 
29 of hospi[INVESTIGATOR_059]  X X8 X X 
Targeted medication review   X4 Daily until discharge  or day 
29 of hospi[INVESTIGATOR_059]  X  X X 
Adverse event evaluation   X4 Daily until discharge  or day 
29 of hospi[INVESTIGATOR_059]  X X X X 
SAFETY LABORATORY         
Type and screen   X3       
Safety hematology, chemistry and 
liver tests   
X4,5,6 Day 3, 5, 8, 11 (all ± 1 day) 
if hospi[INVESTIGATOR_057]5,[ADDRESS_743894] for females of  
childbearing potential   
X2,3      
RESEARCH LABORATORY         
Oropharyngeal swab  or 
endotracheal  sample   X5 Day 3, 5, 8, 11 (all ± 1 day) 
if hospi[INVESTIGATOR_057]  X    
Blood for research   X5 Day 3, 8,  (all ± 1  day) X  X X 
1 Refer to Section 8.1 of the protocol for details of clinical data to be collected including ordinal score, NEWS, oxygen 
requirement, mechanical ven tilator requirement, etc.  
2 Screening laboratory tests include: type and screen , required within [ADDRESS_743895], and PT.  
6 Any laboratory tests performed as part of routine clinical care within the specified visit window will be used for safety 
assessments;  safety labs will not be drawn outside of clinical care . Window during the study period is ±1 day.  
7 In-person visits are preferred but recognizing quarantine and other factors may limit the participant’s ability to return to 
the site for the visit. In thi s case, these visits may be conducted by [CONTACT_566291] . 
8 Phone call at Day 22 is to assess clinical status (ordinal scale), adverse events, readmission to a hospi[INVESTIGATOR_307], and mortality  
only.  
9 Safety laboratory tests on Da y 15 and 29 if still hospi[INVESTIGATOR_566258]. . 
10 The collection of Day 60 data for primary and secondary endpoints and the collection of Day 60 samples for exploratory 
tests may be performed up to 90 days following the Day 60 visit.  
 
12.2 Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric 
Adverse Events, Corrected version 2.1 (July 2017)  
Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events 
(Corrected Version 2.1 - July 2017)pdf 
 